var title_f5_53_5968="Ring around the artery sign";
var content_f5_53_5968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spontaneous pneumomediastinum: Ring around the artery sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral radiograph shows lucent ring (arrow) around extrapericardial segment of right pulmonary artery. This finding is known as ring around-the-artery sign.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Bejvan SM, Godwin JD. Pneumomediastinum: old signs and new signs. Am J Roentgenol 1996; 166:1041. Reprinted with permission from the American Journal of Roentgenology.&nbsp;Copyright &copy; 1996 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5968=[""].join("\n");
var outline_f5_53_5968=null;
var title_f5_53_5969="Rim pattern IF MPGN";
var content_f5_53_5969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rim immunofluorescent pattern in membranoproliferative glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in membranoproliferative glomerulonephritis reveals complement deposition in a rim pattern outlining the glomerular capillary wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5969=[""].join("\n");
var outline_f5_53_5969=null;
var title_f5_53_5970="Vaginal agenesis rudiment horns";
var content_f5_53_5970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69536%7EOBGYN%2F61993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69536%7EOBGYN%2F61993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginal agenesis with rudimentary uterine horns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 285px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEdAXYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8o8T+Pdc1/WLrw58K7S3vbu2byr/WLg/6LYtkgqP+ekgxnAyB6HtT+KnizVda8X2nw38EzPBqd0ol1TUYyP8AQbY/e288ORg/iMcnIwtJfUfEl7deBPhfN/wj/g/RG+z6hrcXzz3EvV0ib+8TnL5z36YBB7G3/wAKt8Wt+/vvi1r4ujhpDFGscQOc8JuwBVidfil4LL3KXVn460hF3NA0QtL1QO6bQVc+3JNMb9nrwTcQt/aLazfXb4Ml3cahIZHb+8e2fwpn/CjIdLdJvB3jHxNoc0akIguvPhz6lGxn6ZoSsF+51Pgv4p+GPFdwtjb3b2Gs/wAemahGYLhW9NrcMf8AdJruq+f/ABhp3iPTrCOP4o6HY+MtCUY/tfSbcx31ienmFRzwCTlOmOau+G9U8SaNo8Wr+Cdc/wCFh+ExgNYzMP7Rt1Po/BcjH3HAb0oEe50Vw1l8V/Bdz4f/ALWn16zsol+WWC6kEc8Mg6xtH97cDxgA+2a5G4+PNnqNw0Hgjwr4h8TEHHnW9sYoT/wIgkfiBQOx7PRXhmn/ABe8dXscc8Hwrvbm2lUyRzW2oK6Mo4PzBCM5B4zmr3h/9oLw5fWUFzrmla7oVvLjF1dWbPbZ6cSLnIz3wKAsey0VkeHfEuieJLX7RoOq2WoRYyTbyhyv1A5H41r0CCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorF1bxZ4e0dmXVdd0uzdRkrPdIjD8Cc1VtfHnhG6Um28UaHIAMnbfRf8AxVK6HZnSUVDaXVveW6T2c8VxA/KyROHU/QjipqYgorJ8TeItJ8MaVLqOvX8FjZxjJeVsbj6KOrH2GTXmkvjLxx4yV5PB2mQeG/DxXcNc11cO6/3o4PTuC3BHpQB6xqF/Z6bbm41G7t7SBesk8gRR+JOK4S7+Nfw6tLowS+KrIyAkExK8i8f7SqR+teQTL8O/7Xc6lNr/AMU/E4OC0KPNArHgKApEar/31iuu0u48dWFgP7N+D+g2mlRnKWIvYVnK/ltz9aAPStA+Ivg7xBMsOj+JNLuZ25WIThXP/AWwf0rq6+fp774XeMtQTSPHPhJvC2vO2EW+t/sjSPn+CdMBxn1IzngV0FzF4j+Er/ara4vfEngRQDcxXUvmXmmIMZdG6yRgZJXqMfU0Aew0VBYXltqFjBeWM0dxazoJIpYzlXUjIIPpU9ABRRRQAVzvxC8Rp4U8GarrLbWltoT5EbDPmTN8saY93Kj8a6KvNPiuv9peL/h3oLn/AEa61V72ZSAQ4tojIAf+BbaAOfOmXXw2+GNzMqpcePfE1wkEtwTkve3BwAD/AHIwWIA4+UnvXpPgDwnYeCvCtlommIBHCuZZP4ppT96Rvcn9MDtXJaqsmv8Ax80mzJJsPDmmPqDrjKm4nLRJn3CBiK9PoAKKKKACvNfEfwwhTWpfEvgS6Xw/4nOS7IubW8yclZ4x1BP8Q5HXk16VRQB8p+KtF8H+OPEOp6V4psrbwX8S0YOshmLWd63BVsnCsG79G/3iCK7qbx/P4bE9j47k1Lwjqc8cMUd5Bbi60seWxO6DCnaXXhlbkcdOtXvj34Ptpns/GY0q31MaZG0GqWUkIc3Fix+dlPUSR8spHI5rmdH0DxlpGkXL+GDZ+JfB91dPFBomqXsdwLm02ApLFMcbScEeWc4x3oA9QtXs73TrfUNFjhutGtWi1DSrXRJfJklDqwbzEJVSpZ2O046HPIpbq11FrJ7Z5hfarNK+nS3Gm7FSwhcl0keCRihZRszwSc+leQeFfBHhXVtcul8A+I/EPgPxSq4utHmJDxr94gRsQXTJyCGIx9a6rVNC+JdnaTQanaaF4usnminkezlbTL2RoiCrFh8pPygY/DpQCOX8aeB/Dl0+p6to2oxeHL2HWoNNtbyy02e2eKTgSKQnEm5uQ4AUdM1t2fxJ13wQuzWWm8XeHl1F9LXUYLZ4b6KZBllkiK7ZABnDKecU7/hZmnHVZ9I1lvGHg/VNbuFIn1QJ9nszGAf3TP8AKEfbtOB1bt1rumvdSm1S5uYo7121KVbGPTJNRiiEdsrMHvoCpJOVZTgc9KAOk8JeKtF8XaZ9v8PahFeW4O19uQ8bf3XU4ZT7ECtuvnmfQoLKey1rwbrmkaRrF1fjTtIvY5prmPV4VXBju+CDJuDfP1+Xr0NegfC34oWXjBpdK1JI9N8UWryR3FgScPsYqXiJA3Lx06jv60AejUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFR3E8VtBJPcyxwwxqWeSRgqqB1JJ6Cs3xR4h0vwtolxq2u3cdpYwD5pH7nsoHUk9gK8S1PTvEnxS1E3PjPSdbsPAptJbuy02ydVnmZMbfPGc72BJVBxn06kA3Na+Ler+ILlbD4U+H59YBuFtn1m5hcWMRJwSCOWA7ngD34rIuvh34j8TPE/j/xZczzy35jTTIrsWlrPbqcu8Sx5ZzsyQDg8c12Gl2b2Wm+HTo/h/VQukaQx0w6hfLamSZhsFtPGDy5Cg7ipAPTmszU7nTtD0qO5TWPDnhzTLOP7FbYgW8k0rVJGLSjf0xtZlI49eBSdluO76HJ2fw5+HOsaNdJo+mtLDcw/wBo6dLa2k8l3JFCwEqM03ylmcMoX5cg/jXTap4J8BRrd6lqPgvR4tLtbCK8ktYIT9vikYnKPDHxjGO55DdhmsvUviRY+J11nRtAs/EfjWK4WG1aPT4RaW0TKMu4uFwVDnHX04466sem/E3VLy41WZ/DXgeGSFY7iZIxe3RjTJXe7YTC7mxz3NO73FZHD3Pw40zwpc2jeGPHn/CO6hLO2qzma4a28rTWztHkMSHZTgfNjPORW74M8f8AxH8QafeW+l2ulXWnQSsqeLdQRrW3kiH8fknBY/T5fWubuk8HDVLi6g0zxB8WvE1uNkt2ytLaQ45C5GUA56AN3rX+Huk618abybWPHnlw+ELCY29lotm5WCWRMAsxU/Oq9M5wTnGACCrXHsZuly6dc+IJ5vCllf8AxJ8cK651zUFxptm3+wc7VA7Afga9Is/hNN4gnhv/AIo63P4hulJZdPiJgsIT6LGuC+PVjz3Fem6XptlpNjFZaXaQWdpEMJDBGERR7AcVbpiKmlabY6TZR2el2dvZ2sY2pDBGEVR9BVuiigDL8SaBpfibSJ9M12yhvLKYYaOQfqD1B9xzXl1vPqPwk1S00vW7yXVfAGoSi2try6bfLpbtwsUrfxRHoGPTv7+y1meJ9Ht/EHh3UtIvUD297bvA4IzjcCM/UHn8KAOC8K28vgDx4vhdJN/hjWlmutIQj/jznU75bcf7BUl19MEV6hXz8upTXvwC8Oa/cbzq3hG9ga46lwbeXyZgfXMRYn617/FIk0SSxOrxuAyspyGB6EGgB1FFFABXmvjJQfjd8OTIu5fs+p7M9Ffy4+R74yK9KrzT4u7bDxF8PddchYrPWhayuSQES4iaPJPpu2/nQAuiTeR+0B4ntpAqtdaJZzx+rqkkik/gWx+VelV5t8WILnQtR0bx3pkDyvo5aDUo4xlpbCTHmcYOSjBXA9mr0HTr221Kwt72wnjuLS4jEsUsZyrqRkEGgCxRRRQAUUUUAMmiSeGSKZFkidSrIwyGB4II9K8DudIPwx12z0QWWlN4WvtWS+0e+vlcppt0SA8TlTkZXd5bHjPBzzj3+qOt6TYa7pdxpur2kV5Y3C7ZYZVyrD/HuD2NAHkfiDw7Y6sdFlaZ7CKaa5Fne6pLJHrMd7vJiW3Z/wDlmdrHY3BUitr4b/EPULiSx8PfETTpND8VyR5i84AQ34HeNgSu/wBUz9Pbkpr3W/hjr6aZ4q1C2vvCbROvh/U9Rt/OFndE/uo55B84AXcN3p3HIG9qvhDSvEkcen3WnPqA8QSifVdW0m+3Q6fdwoCpjDligY5XgfXtQB6br+h6X4h0yTT9bsbe+spPvRToGH1Hofcc14lrnww8W+B7v+1fhfeW2oW9rbyxWumaogllsw4Jb7PI3PXB2kjPfOaseHPEvjDwBpzya7o+san4NguJLZJJ1EmpWUan5XcLxLEezcED2xn1/wALeJ9G8V6YmoeHtRt761b+KJuVPoy9VPsQKAPKtG8Rf8JX4Nvrmx1XxJBPEbfTrjT7DTYo7uxuw6mSZUAyA247uwG7HIqL4heFb3xFrdtHb61caNrQ1dpNOn1SVTJtjgBY2Sxn7jcFlb0PSuy8e+Ajf3w8S+EpE0rxjarmK5QYjuwP+WNwo4dW6ZPI4IPFcx4F8Q22rrb3E8Nvpeq2t5fW0ujahKstzJqBUOwt5nYmNfmYAAYwfQUAdN8IPHF14q0d7PxFaPp3imwAW9s5YmhZlJIWZUbna2PoDkeleg189eKNO1rS7jw3qmkSazb+JNA0ebUJbW/AuxdQ+aDLby3YxuYDO1cHtjBr3fQtUtNc0ax1XTpPMs7yFJ4m9VYZH480AXqKKKACiiigAooooAKKKKACiiigArM8S65p/hrQrzWNZuBb2Fom+WQjOOcAADqSSAB6mtOvDPiHqa+LviHd6Q09pF4e8J2bX95LfZFnJfsP3KTEdVTcGK9yCKAMi1Or/EnxP4b8UaxqFrpOmnUT/Ynh7U7ViLmNFy8p5AMhXLKeQMce/TSx6XcWt5dacdPnT+2jdaGLbX5I/wC0LsjMqO2SF5BHljI46c5Oov8AbEscNvaa5c32q6xHHv1CwjhuLPRpFhBDpG3ISXnGSetcRo9nqfxU8Q6hZ6XfS2Hw6tnTzCumx20styMiVYWAyNx3Fn6jdtpW6Dv1H6jfz614wuNI+HHhzSdZCXS6te6pe3ck1tYakcjKtnBKjB2p69Biur8O/BLRE1KbWfGMg8Ra3dTG5n82MR2okKgErAvyn6tknr1rv7Cy0LwX4dMNpFZ6Ro1mhZuRHGg7sxPf1J5NeZa/461fxxY3K+BJptF8M26u+oeKbmDCrGqksLdDhmP+3jjHFP0Dc6fxp460D4eW9rpGnWBu9XmAWy0TTIh5jjOAdqjCL7n04zXnd34c8S/EUapP8RNV1DS7KydVHhzSYyizkJ5mzzG4nYjj5cjPTFaPhTw5p3gW3g1exuDc61cx28H9ralfeTba09wwbIJLPvVVO0ccnvkkZXjTxNdQ+LLTwb4Uik1rVdI+S1s9TgaWdLraWS9Nwxx5aK+OTknjBBzSYLbQqa5a22rTL8PfAfhrUdGXWRbaxqUqXJtzpYZgrI8QyFJRPuZ5LA4NfQegaRZ6BollpOlxCGys4lhiT0UDv6nuT61ifD3wbB4R06cyXEl/rN84n1HUZv8AWXUvqfRRnAUcAV1dMQUUUUAFFFFABRRWT4r1208M+G9R1rUW22tlC0rf7WOij3JwB7mgDznwBEl1ofxUsruItpx1zUUAUZ3K0alwPxLfiTXS/BGea4+EfhKS6cPJ/Z0S59gML+OAK4+1F94S/Z11nUNVPla5qNvc30o6EXN0xKJj1BdBj1FemeCNI/sDwboekEKGsrKGBtvTcqAN+uaANuiiigArnfiF4bi8XeC9W0OVthu4Csb/ANyQfMjfgwBroqKAOT+GWvnxX4E06+vY9t6YzbX0Lj7lxGSkqkf7ynj0IryPxTBcfCnWYIPA3jPStM0zUJpCNI1sPJaQSDDMqSqp8r7y/KSOucmt/wARf2h4W+K+o2WjapHp1p4s0q5u0Z13La38CDM+CCMFAM+uPYV5zca3qmo+H9E8W2epaJa6b4llSy17+0LMXFrFfQq6LKUIwgkVQCfdTQBH4k1v4m+NtTuNHb7be2cR8t08MxtbWry5HyvdSjleucZH8693+C3hHVPBfgiHTdc1KW/vnladg0hdbfcB+6RjyQMHnjJJr588PWniW2l1G50rR9V0oaZdy210fCV2zBJQeGewmYhlYEEbcAqc16r8GPivceJfEL+GdWuI9RvUtzOl7FaPbOCpw0c8TcI/QgqSp+tHyBntVFFFABRRRQBU1fTbLWNNuNP1S1iurK4QxywyruVga8M8QeDJ/h3pM2m22kz+IfhxNP8Aa7izgYpe6c4IbejqwaVMjODyAOuK9+ooA8c8OeI7LxZbX2veGf7H1Pxdc2wt5dNGqSLGLMTEBnQjKPtPPy9TjPPPN654F8NTQteeBJ9L8OuwS10LV9P1dovtl3lg0MgGd2CpHcnmvQPGHwn0rVtUk13w7dXPhrxOVIGo6c2zzM9RLH91we/Qn1rz68vfHHgm5trbxhpAu/DFtbukd74csInWOcnK3TxFcxumScgAZz1osBJpus/Eu1n+xWvjrwbqoN22mRy39vJFK10oBeMBFALD1yQa6Pw3Zy6Do2t6nqmp2U+oyTx6xdeI5LZZLE8+W0cIVsgpGhXPBy2eelN8N+O/D+rafez6L43EuoafpawrPq7pFbSStlhO8XytvUjax44OOc5q/qsUWjW2sX9zL4d0lLLSorKC5id3t0kmbL+Zaj5QpkIKnkkE5PWkmug7MZNpr6Za3f8AY2h6k1npVwNU0qKz1gH+2DKuZQVYkhBvPyng5460vwCuZbW08ReGpYHt4tIvg9rC7qzQwXC+csTFSRlCzKcemO1VPFuqromsXOp6ze+CYdX0jS0TTri5upI5RLIoEgeFTkRthtoGT+Zqn+zroNvFfeI/E2j6UdJ0HVRBHZQMzkzeWGMk4DkkIzMdoPYU15Cfme20UUUAFFFFABRRRQAUUUUAFFFFAFLW79dL0a/1B0LraW8k5UdWCqWx+leIfCW4trfwJpt3qS6nMmoQXviDVTb2K3Nteb2KmGRsMS6jBCDBOOfSvavE1i+qeHNVsISBLdWksCE44LIVHX614X8JL63vfCHhzw9c6xe6PLZ3KWn2LS4XjnjvIfMaZLiQAqUkBVuQMnPOQaAJvFsmoah4E1S08J3fh2XXtYtPt1zPGh0+ZNLG7yWI4OVA2ZboDj3qDw38T/EFp4X0TRfBnwxv43Nqn2czy4t9nAMgIGXXJyWyOuSa7WLUNT1W4tYoL+ZZtbupJoItU0Ir5FjGcS20h7FuoLdQfcUWt5Z3LWt1o93oSCW5/s7QriHSJM2sSczwucgAERsAflXOOtAHLal4J1nxMNcm+JkWteIJrDy2ttK0xha2E28ZxCdwaRk5BZ8Y967a006S11exBhEk9oZdO01NPd3gsYGhBT7ZGXwW+XGR6j61wOueI/CXhnXb6wj0fUNT1CDWIdQsILLVmuZr64dW3uI1YlFTptbg56Ve8M+FvH/jGG+fxUbLwlpeozGa7i0yIR6heAHCrLICQoCgLkckDkcml6Dem4msa7f6trEnhzwZPBrXii6EJ1LUT+903R5ITtMiRPuCOcHCjuAea9I+H3giz8IWlxK0zahrl85l1DVJlAluZCc/8BUdlHArV8KeGdH8J6RHpnh+whsrNOdqDlz/AHmY8sfc81s09hBRVXVNQtNK0+e+1G4itrSBd8ksrBVUe5NGmahZ6rYxXumXUF3aS58uaBw6NgkHBHB5BH4UAWqKKKACiivlb4o+FPE+h67qviDxlq0Ws6LI5NoDrjaa0QySsaoFIJxgYXOevrSdxo+odQvbXTrOW71C5htbWIbpJpnCIg9STwK8she4+LeuWdyIDD4A0y68+NpMhtYnQkKwHaFW55+8QPw8O8C32iXEsF9428JeILvT5pCbKO81WW7kunxlVjtSq+aB/e+6M85PFfWN1qljoPg+XVJLb7DYWNkbk2xVYzCipu2bRwCMYwO9C7sXocf4/ceJ/H3hvwdEA1vbOuuamdoIEUTYhjP+/Jg/Ra9LrgfhFos8Gk3PiXWUH/CQeInF9dfNu8mM/wCpgU/3UQgfXNd9TAKKKKACiiigDwP4+Xm3xrbvbv5cmk+GNVvJ3HdZUEMan2L4rkfG3hmy8G+DNR0LVHNvoviHRYrq2dvljt9VtYlJX0UyhR9SCK9Dvvhbreu/F3Vda16+tG8LXDW7i1iZ/NnWFcxxOMABPMO8jJyQK9T8R6BpXiXS307XrCC+smZXMUy5G4HII9DQB558IPAWseGdUXU77XhqWnzaVDawK0WybAIdfNI4coCyq3XacdBXqaQQpM8qRRrK+A7hQC2OmT3p6KqIqIoVVGAAMAD0paBBRRRQMKKKKACiiigAooooA4rxX8LfBXiku+seHrJ7h+s8KeTKT6lkwT+Oa4ib9m/wgHc6dqPiHTxJjzFt73iQDoDlSeK9soovfcVjzTw18EvBGh3qXradJql+pBW51OY3DDAwOD8vHbivSlUKoVQAoGAB0ApaKAsFFFFAwooooAKKKKACiiigAooooAK8o8afDLXbjxXfeIvAfiyTw7fajGkd9AYBJFOVBUP7Ng9cH6jNer0UAeEW3w7+L6Naq3xOhVLXcEb7MXZ9x/jBHz+27OO1aS/BW+1dAPG3j/xJrMbcy20Mv2aB/bYM8flXstFAXOa8HeBfDXg2AxeG9HtrIsMPKoLSP9XbLH6ZrpaKKACquqX9tpem3N/fyeVaW0ZllfaW2qBknABJ/CrVYHjzw8ninwlqOkPJJG08f7p0laPbIvzISR2DAZHNAHML8SfDOq3eowXt7Zw6FFZn7QdQUxecWkaPbtcDA+RhtPLbhgcHPKfDbT/F2l6vreoWGo2uvaWpS2s7CW5Ebx22N1uAUXylULKGLqXynAUMNtZ1l4Y1jxAmrSaZfaFqWupcTQXQuVYx6e6TboxFuQsw3RkYb5eEG1lVWr2/w/prabp0Uc8izXrIn2mZAVWWQKAz7STgnGT696BlyxeeSyt3u4xFctGpljByEbHIz3wc1PRRQIK+f/ix8KmuPGOpeP8AXPGT2WkWcSyrEbNZ2t1VQNqbiVyW5Hy9W9ea+gKr6jY2mpWUtnqNtDdWko2yQzIHRx1wQeDQB8UeHdY8QarHKPDuk3yjxBfro6eJdSnaa8aF85iQnCrgBmYoMADB7Gu21exWfQPiQtl9rn0d9a0rREf7QX/cQNGjgNnnJbB/3qj8R6vcePvibLonhG4htms5JdH0yGL5EsYlXF1elV4BIJjTpnPHIq54j8Na54I8LeIfh7pXhXUNa0nV7pZ9H1GB93kStsIEp/hKNHuDcA/SgZ9PxosaKiAKqgAAdhTqitFkW1hWdt0wQB29WxyaloEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGRBoi2/iS41aG6mVbiJUltcDy2Zc4fPXOCRjOOScZOa16KKACjNFFABRRRQBieH/AApoPh2e7n0TSbOynu3Mk8kMYDSEnJyeuM9ulbdFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFGACT3NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRjnNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFJzk9MUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQBigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorI1vxNoWhSImt6zp2nyOMqt1cpEWHqAxHFAGvRWfo+t6XrUJl0fUrK/iU4L2s6ygH3Kk1oUAFFFFABRSEgdSBmloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuS+IXj3SPA9hFJqLSXF/ct5dnp9uN091ITgKi/Ujn+vFAEfxI8ax+E7G3t7K3OoeItRbyNN05PvTSH+JsfdRerMeMCuDsPhb4bsIZvEvxgvbHVNfvm3XE99P5VtCT0iiUkDAHH4cAVmwX914S1J/GHjG3Op/EXxAn2bR/D9v8zWsOciIHsBnLv9ffO/pvwkfxRdxa58Wbo61qhGYtOjcpZ2QPOxQvLn1JPOO/WgZz6/DP4R61dST+EfEqaTev8gbSNYUEHP8AdJP5CteHwd8WtCV00Dx7YavaBcRJrFr8/wCLqCSfcmuj1T4JfDvUlxN4XsojjaDbF4D/AOOEc+9YV18AdChVD4b13xJoUyHh7W/ZhjuMH/GgWhDNd/HRI4ImtvBCOzBTMZJeT9Cf5VLdeEfi3rxSDWPHGl6TZ7syHRrVhKw9AzYI/A1Qk/Z4sr5JjrvjDxJqswjP2R7i4J+zSdpAM8kcccf4Wrb4T+M9QT7N4q+J+s3Gnp8qxWEYt3kX/bfJJz75+tL5DMnXvhF8PreRZPGXjjVJdRH+snv9ZjR2P0YcfStO08Eap4f01NZ+EHi641SFOTpmoXgu7S6A6qjj7jdOc/lXQ6R8Dfh5pq/8i9DeSk7mlvZHmZj77jj9KzNX8N3Xwv1WTxH4E05pvD0wH9r6DbLzgA/6RAP74GMoPvAfkxeh3HgDxXF4t0Rrk20ljqNtK1rf2Mv37WdfvIfUcgg9wRXTV5DqxOqfZviX8LbiO/uDEE1DT4zgalCv8DD+GdBnbkZ7egr0Xwh4jsvFfh611jTBMtvOD8k0ZR42UlWVge4II/CgDZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryPXfAU3hm+1nxX4Z0w+JvGGoXa/Zn1SYFbBGOPkJ6IuT05xgdBz65RQB598N/hynhu7m13X719b8X3i4udSmydin/AJZxL/Cg/X2HA9BoooAKKKKACiiigAooooA8z8Q+ENR8Na9J4p+HNtCbqdv+JpoxcRQ6gv8AfUnhJhk4boc8+/pFtI0tvFI8TQs6hjG2MoSM4OOMipKKACiijv7UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAM9+tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Of note, in cases of vaginal agenesis the uterus may be normal or exhibit a variety of malformations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with noncommunicating uterine horn (containing an endometrial cavity) not fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012.&nbsp;Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5970=[""].join("\n");
var outline_f5_53_5970=null;
var title_f5_53_5971="Patient information: Peptic ulcers (The Basics)";
var content_f5_53_5971=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15735\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"         Upper digestive tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/31/19954\">",
"         Patient information: H. pylori infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/58/14242\">",
"         Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/60/964\">",
"         Patient information: Peptic ulcer disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/0/21506\">",
"         Patient information: Upper endoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/24/5506\">",
"         Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Peptic ulcers (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/peptic-ulcers-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1480785421\">",
"      <span class=\"h1\">",
"       What is a peptic ulcer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A peptic ulcer is a sore that can form on the lining of the stomach or duodenum. The duodenum is the first part of the small intestine (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785428\">",
"      <span class=\"h1\">",
"       What are the symptoms of a peptic ulcer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with peptic ulcers have no symptoms. Other people can have symptoms that include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain in the upper belly &ndash; Ulcers in the stomach often cause pain soon after a person eats. Ulcers in the duodenum often cause pain or burning when a person&rsquo;s stomach is empty.",
"       </li>",
"       <li>",
"        Bloating, or feeling full after eating a small amount of food",
"       </li>",
"       <li>",
"        Not feeling hungry",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by other conditions. But if you have these symptoms, let your doctor or nurse know.",
"     </p>",
"     <p>",
"      Sometimes, peptic ulcers can lead to serious problems. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bleeding &ndash; This can cause smelly and black-colored bowel movements or vomiting blood.",
"       </li>",
"       <li>",
"        A hole in the wall of the stomach or duodenum &ndash; This can cause sudden and severe belly pain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785435\">",
"      <span class=\"h1\">",
"       What causes peptic ulcers?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common causes of peptic ulcers include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An infection in the stomach or duodenum caused by a type of bacteria (germ) called &ldquo;H. pylori&rdquo;",
"       </li>",
"       <li>",
"        Medicines called &ldquo;nonsteroidal anti-inflammatory drugs&rdquo; (NSAIDs) &ndash; NSAIDs include pain-relieving medicines such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil or Motrin), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sold as Aleve or Naprosyn).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785442\">",
"      <span class=\"h1\">",
"       Is there a test for a peptic ulcer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of a peptic ulcer, your doctor might do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tests to check for H. pylori infection &ndash; Doctors can check for H. pylori infection by doing:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Breath tests &ndash; These tests measure substances in a person&rsquo;s breath after he or she has been given a special liquid to drink",
"       </li>",
"       <li>",
"        Lab tests that check a sample of a bowel movement for the infection",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A procedure called an &ldquo;upper endoscopy&rdquo; &ndash; During an upper endoscopy, a doctor puts a thin tube with a camera on the end into a person&rsquo;s mouth and down into the stomach and duodenum (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 2",
"        </a>",
"        ). Then he or she looks at the lining of the stomach and duodenum for ulcers.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785449\">",
"      <span class=\"h1\">",
"       How are peptic ulcers treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the cause, but most peptic ulcers are treated with medicines.",
"     </p>",
"     <p>",
"      People with H. pylori infection are treated with 3 or more medicines for 1 to 2 weeks to get rid of the infection. This treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to reduce the amount of acid that the stomach makes",
"       </li>",
"       <li>",
"        Different types of antibiotics",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people need to take medicines that reduce the amount of acid for a longer amount of time. Some people take these medicines for the rest of their life.",
"     </p>",
"     <p>",
"      It is important to follow all your doctors&rsquo; instructions about taking your medicines. Let your doctor or nurse know if you have any side effects from your medicines.",
"     </p>",
"     <p>",
"      People who have serious problems from their peptic ulcers might also need to be treated with surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785456\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, people often have follow-up tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tests to check that the H. pylori infection has gone away",
"       </li>",
"       <li>",
"        An upper endoscopy to check that the peptic ulcer has healed",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785463\">",
"      <span class=\"h1\">",
"       What else can I do to help a peptic ulcer heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help a peptic ulcer heal and to prevent future peptic ulcers, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not smoke",
"       </li>",
"       <li>",
"        Not take NSAIDs (if possible)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1480785470\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       Patient information: H. pylori infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       Patient information: Peptic ulcer disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       Patient information: Upper endoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"       Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/53/5971?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15735 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5971=[""].join("\n");
var outline_f5_53_5971=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785421\">",
"      What is a peptic ulcer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785428\">",
"      What are the symptoms of a peptic ulcer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785435\">",
"      What causes peptic ulcers?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785442\">",
"      Is there a test for a peptic ulcer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785449\">",
"      How are peptic ulcers treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785456\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785463\">",
"      What else can I do to help a peptic ulcer heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1480785470\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"      Upper digestive tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"       Upper endoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=related_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_53_5972="Ligasure division";
var content_f5_53_5972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LigaSure&trade; division",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ileocolic artery after division with LigaSure&trade; device.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jon Gould, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5972=[""].join("\n");
var outline_f5_53_5972=null;
var title_f5_53_5973="Dorzolamide and timolol: Patient drug information";
var content_f5_53_5973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dorzolamide and timolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/39/13943?source=see_link\">",
"     see \"Dorzolamide and timolol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cosopt&reg;;",
"     </li>",
"     <li>",
"      Cosopt&reg; PF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dorzo-Timop;",
"     </li>",
"     <li>",
"      Cosopt&reg;;",
"     </li>",
"     <li>",
"      Cosopt&reg; Preservative Free;",
"     </li>",
"     <li>",
"      Sandoz-Dorzolamide/Timolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dorzolamide, timolol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, slow heartbeat without a working pacemaker, or wheezing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use the oral timolol and the eye drug at the same time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12397 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5973=[""].join("\n");
var outline_f5_53_5973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161900\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161901\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023775\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023777\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023776\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023781\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023782\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023784\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023779\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023780\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023785\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023786\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/39/13943?source=related_link\">",
"      Dorzolamide and timolol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_53_5974="Verapamil: Patient drug information";
var content_f5_53_5974=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Verapamil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     see \"Verapamil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"     see \"Verapamil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calan&reg;;",
"     </li>",
"     <li>",
"      Calan&reg; SR;",
"     </li>",
"     <li>",
"      Covera-HS&reg; [DSC];",
"     </li>",
"     <li>",
"      Isoptin&reg; SR;",
"     </li>",
"     <li>",
"      Verelan&reg;;",
"     </li>",
"     <li>",
"      Verelan&reg; PM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Verap&reg;;",
"     </li>",
"     <li>",
"      Apo-Verap&reg; SR;",
"     </li>",
"     <li>",
"      Covera-HS&reg;;",
"     </li>",
"     <li>",
"      Covera&reg;;",
"     </li>",
"     <li>",
"      Dom-Verapamil SR;",
"     </li>",
"     <li>",
"      Isoptin&reg; SR;",
"     </li>",
"     <li>",
"      Mylan-Verapamil;",
"     </li>",
"     <li>",
"      Mylan-Verapamil SR;",
"     </li>",
"     <li>",
"      Novo-Veramil;",
"     </li>",
"     <li>",
"      Novo-Veramil SR;",
"     </li>",
"     <li>",
"      Nu-Verap;",
"     </li>",
"     <li>",
"      Nu-Verap SR;",
"     </li>",
"     <li>",
"      PHL-Verapamil SR;",
"     </li>",
"     <li>",
"      PMS-Verapamil SR;",
"     </li>",
"     <li>",
"      PRO-Verapamil SR;",
"     </li>",
"     <li>",
"      Riva-Verapamil SR;",
"     </li>",
"     <li>",
"      Verapamil Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Verapamil SR;",
"     </li>",
"     <li>",
"      Verelan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to verapamil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703676",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low blood pressure, Lown-Ganong-Levine syndrome, very weak heart, slow heartbeat without a working pacemaker, or Wolff-Parkinson-White syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have muscular dystrophy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gum changes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take liquid (suspension) or tablets with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take long-acting products with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect liquid (suspension) from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11903 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-235EC14115-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5974=[""].join("\n");
var outline_f5_53_5974=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023338\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023340\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023339\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023344\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023345\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023347\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023342\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023343\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023348\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023349\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=related_link\">",
"      Verapamil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=related_link\">",
"      Verapamil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_53_5975="Histology case 4 with answer";
var content_f5_53_5975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Histology case 4 with answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correct answer is the light micrograph shown in panel B, which shows intracapillary thrombi characteristic of the",
"    <strong>",
"     hemolytic uremic syndrome",
"    </strong>",
"    . The differential diagnosis of postpartum acute renal failure includes the hemolytic uremic syndrome and preeclampsia (panel A). Timing of the onset of renal failure with respect to delivery is often helpful in distinguishing between these two diseases. In this case, the onset of renal failure one month after delivery is consistent with the hemolytic uremic syndrome, while postpartum preeclampsia occurs one to two days after delivery. Panel A shows swelling of damaged endothelial cells, leading to partial closure of many of the capillary lumens (arrows), reflecting the glomerular endotheliosis of preeclampsia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5975=[""].join("\n");
var outline_f5_53_5975=null;
var title_f5_53_5976="Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility";
var content_f5_53_5976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/53/5976/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5976/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/53/5976/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5976/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/53/5976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5976/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/53/5976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ectopic pregnancy has dramatically moved away from a primarily surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/1\">",
"     1",
"    </a>",
"    ]. Currently, most women with unruptured ectopic pregnancies are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . However, some women undergo surgical therapy by choice or by necessity, if they are not good candidates for medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical treatment of ectopic pregnancy and prognosis for subsequent fertility will be reviewed here. Risk factors, clinical manifestations, diagnosis, and pathology of ectopic pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=see_link\">",
"     \"Incidence, risk factors, and pathology of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for surgical rather than medical therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Impending or ongoing rupture of ectopic mass",
"     </li>",
"     <li>",
"      Contraindications to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      Coexisting intrauterine pregnancy",
"     </li>",
"     <li>",
"      Not able or willing to comply with medical therapy post-treatment follow-up",
"     </li>",
"     <li>",
"      Lack of timely access to a medical institution for management of tubal rupture",
"     </li>",
"     <li>",
"      Desire for permanent contraception",
"     </li>",
"     <li>",
"      Known tubal disease with planned in vitro fertilization for future pregnancy (only in patients who are otherwise good candidates for surgical therapy)",
"     </li>",
"     <li>",
"      Failed medical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, women with a serum beta human chorionic gonadotropin (hCG) concentration greater than 5000",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    before treatment or fetal cardiac activity on ultrasonographic examination are more likely to experience treatment failure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In hemodynamically stable women, surgical intervention should only be considered if a transvaginal ultrasound examination (TVUS) clearly shows a tubal ectopic pregnancy or an adnexal mass suggestive of ectopic pregnancy. If no abnormality is imaged sonographically, there is a high probability that a tubal pregnancy will not be visualized or palpated at surgery. Therefore, these women should be managed conservatively with either medical therapy or expectant management. A repeat ultrasound examination after a few days may visualize an abnormality, thus enabling a surgical procedure, if this option is desired. We do not perform dilation and curettage to rule out a failed intrauterine pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of surgical treatment are less time for resolution of the ectopic pregnancy and avoidance of the need for prolonged monitoring. Medical treatment, primarily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , is the preferred alternative to surgical therapy of ectopic pregnancy, but requires laboratory monitoring after drug administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In almost all settings, expectant management is not consistent with the local standard of care. It is safe in only rare circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=see_link\">",
"     \"Expectant management of ectopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Salpingostomy versus salpingectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of salpingostomy or salpingectomy for treatment of ectopic pregnancy is controversial; randomized trials comparing these two procedures have not been reported (but are ongoing). Operative morbidity is similar for both procedures. The disadvantage of salpingostomy is the potential risk of persistent or recurrent ectopic pregnancy. Thus, leaving the affected tube in situ is best justified if it results in a higher rate of future intrauterine pregnancy than salpingectomy.",
"   </p>",
"   <p>",
"    A review of cohort studies comparing fertility outcome after salpingostomy and salpingectomy for tubal ectopic pregnancy did not find an overall beneficial effect of salpingostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of future intrauterine pregnancy was not consistently higher after salpingostomy than after salpingectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/1-9\">",
"     1-9",
"    </a>",
"    ], whereas the risk of repeat ectopic pregnancy was slightly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/2\">",
"     2",
"    </a>",
"    ]. Discordancies in reproductive outcome among these studies likely reflect tubal status at surgery, rather than the choice of surgical procedure. Salpingectomy does not appear to compromise the rate of subsequent intrauterine pregnancy in women whose contralateral fallopian tube appears to be normal and avoids the complication of persistent or recurrent ectopic pregnancy in the same tube [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We perform salpingostomy in women who are hemodynamically stable and appear to have a reasonable probability of future normal tubal function in the affected tube. We perform salpingectomy, instead of salpingostomy in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncontrolled bleeding from the implantation site",
"     </li>",
"     <li>",
"      Recurrent ectopic pregnancy in the same tube",
"     </li>",
"     <li>",
"      Severely damaged tube",
"     </li>",
"     <li>",
"      Large tubal pregnancy (ie, greater than 5 cm)",
"     </li>",
"     <li>",
"      Women who have completed childbearing (with or without a tubal sterilization procedure), or who will be treated with in vitro fertilization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these situations, there is a low probability of future normal tubal function and the risk of persistent or recurrent tubal problems is high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laparoscopy versus laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic surgery is the standard surgical approach for ectopic pregnancy. Most ectopic pregnancies, even in the presence of hemoperitoneum, heterotopic pregnancy, or interstitial pregnancy, may be treated by a laparoscopic procedure. However, the surgical approach depends upon the experience and judgment of the surgeon and the anesthetist, and the clinical status of the patient. In the case of a patient with evidence of hemoperitoneum on imaging, ectopic pregnancies usually bleed gradually. The surgical approach depends on the surgeon&rsquo;s preference and expertise in laparoscopy and the level of comfort of the anesthesiology team. We perform laparoscopy in these cases, but some surgeons prefer laparotomy for these women.",
"   </p>",
"   <p>",
"    The benefits of laparoscopy were illustrated in a systematic review of randomized trials that compared laparoscopic salpingostomy with the open surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/2\">",
"     2",
"    </a>",
"    ]. Laparoscopic salpingostomy resulted in significantly shorter operation time (73 versus 88 minutes), less perioperative blood loss (79 versus 195 ml), shorter duration of hospital stay (1 to 2 versus 3 to 5 days), shorter convalescence time (11 versus 24 days), and, therefore, lower costs.",
"   </p>",
"   <p>",
"    Laparoscopic salpingostomy also resulted in a higher rate of persistent trophoblast than salpingostomy via laparotomy (OR 3.5, 95% CI 1.1- 11; actual risk",
"    <span class=\"nowrap\">",
"     9/78",
"    </span>",
"    [11.5 percent] versus",
"    <span class=\"nowrap\">",
"     3/87",
"    </span>",
"    [3.4 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there were no significant differences in the rate of subsequent intrauterine pregnancy or repeat ectopic pregnancy. The higher rate of persistent ectopic pregnancy following laparoscopic salpingostomy may reflect the experience of the laparoscopic surgeon.",
"   </p>",
"   <p>",
"    Removing the products of conception piecemeal with forceps may lead to retained trophoblastic tissue, particularly in the area of the tube proximal to the ectopic gestation. We suggest flushing the gestational products out of the tube using suction irrigation under pressure. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Persistent ectopic pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Use of single port laparoscopy (also referred to as laparoendoscopic single-site surgery [LESS]) for ectopic pregnancy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The only comparative study to-date reported that women with a tubal pregnancy who underwent salpingectomy with LESS compared with conventional laparoscopy had similar outcomes for operative duration, blood loss, and hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=see_link\">",
"     \"Laparoendoscopic single-site (single port) surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Procedure for laparoscopic salpingostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear salpingostomy is the standard approach for management of ectopic pregnancy in women who wish to preserve their fertility. The ectopic pregnancy is identified and the tube is immobilized with laparoscopic forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/16\">",
"     16",
"    </a>",
"    ]. A 22-gauge needle is inserted through a 5 mm portal and used to inject a solution of vasopressin (0.2",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    of physiologic saline) into the wall of the tube at the area of maximal distention; this helps to minimize bleeding at the salpingostomy site. Using laser, unipolar needle electrocautery, ultrasonic cutting and coagulation device (eg, Harmonic Scalpel&reg;), or scissors, a 10 mm longitudinal incision is then made along the antimesenteric border overlying the ectopic (",
"    <a class=\"graphic graphic_figure graphicRef72097 \" href=\"UTD.htm?15/1/15380\">",
"     figure 1",
"    </a>",
"    ). The products of conception are released from the tube using a combination of hydrodissection with irrigating solution under high pressure and gentle blunt dissection with a suction irrigator. The specimen can then be placed into a laparoscopic pouch and removed from the abdominal cavity; it is also useful for removal of large fragments of placental tissue.",
"   </p>",
"   <p>",
"    The tube is carefully irrigated and inspected under water for hemostasis. Bleeding points can be controlled by pressure or coagulated with light application of bipolar coagulation. In order to avoid excessive coagulation to the tube, we use a microbipolar forceps. If bleeding persists, vessels in the mesosalpinx can be ligated with 6-0 polyglactin suture (",
"    <a class=\"graphic graphic_figure graphicRef54391 \" href=\"UTD.htm?3/13/3283\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The placental bed inside the tube should not be coagulated because this will seriously damage the tube. The incision is left open to heal by secondary intention; the subsequent rates of fertility and adhesion formation are similar after secondary intention or primary closure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Procedure for laparoscopic salpingectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several methods for laparoscopic salpingectomy. One approach is to bring the fallopian tube through a pre-tied surgical loop using a grasping forceps (",
"    <a class=\"graphic graphic_figure graphicRef66069 \" href=\"UTD.htm?26/52/27461\">",
"     figure 3",
"    </a>",
"    ). The knot is tightened and a second loop is similarly placed. The tube can then be resected and removed.",
"   </p>",
"   <p>",
"    Alternatively, electrosurgery can be used to fulgurate vessels in the mesosalpinx followed by resection of the specimen with scissors (",
"    <a class=\"graphic graphic_figure graphicRef50215 \" href=\"UTD.htm?25/57/26516\">",
"     figure 4",
"    </a>",
"    ). The cornual portion of the tube is desiccated close to the uterus. It is important to elevate the tube and apply the coagulation very close to the tube to avoid inadvertently damaging the ovarian vessels.",
"   </p>",
"   <p>",
"    A partial or segmental salpingectomy can also be done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Procedure for open salpingectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparotomy is rarely performed due to the widespread acceptability of laparoscopy. Total salpingectomy is accomplished by placing a clamp across the mesosalpinx and then placing a second clamp across the proximal portion of the fallopian tube as close as possible to the cornua (",
"    <a class=\"graphic graphic_figure graphicRef61769 \" href=\"UTD.htm?27/47/28400\">",
"     figure 5",
"    </a>",
"    ). The tips of the clamps should touch to completely occlude the vessels in the mesosalpinx. The tube is then excised and the pedicles ligated using a 2-0 or 3-0 synthetic absorbable suture.",
"   </p>",
"   <p>",
"    If the tubal damage is confined to the tubal segment containing the ectopic gestation, a partial salpingectomy can be performed. The clamps are placed proximal and distal to the ectopic gestation.",
"   </p>",
"   <p>",
"    The decision for partial versus total salpingectomy depends on the patient's age and desire to conceive. In general, we perform partial salpingectomy to allow the option for tubal anastomosis at a future date. However, in women who will undergo IVF treatment, we prefer total salpingectomy to decrease the possibility of tubal stump pregnancy and the development of hydrosalpinx of the proximal portion of the tube. The presence of a hydrosalpinx decreases the in vitro fertilization pregnancy rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cornuostomy or cornual resection of interstitial pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, cornual resection and hysterectomy were the most common procedures for treatment of interstitial pregnancy, probably as a result of delayed diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. More recently, widespread use and availability of transvaginal ultrasound and sensitive beta-hCG assays has allowed diagnosis of these pregnancies at an earlier gestational age and prior to rupture, thus providing an opportunity for conservative medical or surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We initially treat these patients medically [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/19,23-25\">",
"     19,23-25",
"    </a>",
"    ], resorting to surgical therapy if there is any deterioration in clinical status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=see_link\">",
"     \"Methotrexate treatment of tubal and interstitial ectopic pregnancy\"",
"    </a>",
"    .) Our preference is laparoscopic removal of the gestation via cornuostomy, with resection of the interstitial portion of the tube (cornual resection) if necessary (",
"    <a class=\"graphic graphic_figure graphicRef52644 \" href=\"UTD.htm?25/13/25808\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dilute intramyometrial vasopressin is injected into the cornual myometrium at the commencement of the operation to minimize blood loss and improve visibility. Alternatively, hemostasis can be achieved by ligating the ascending branches of the uterine vessels. If a cornuostomy is planned, the products of conception can be removed with hydrodissection, grasping forceps, aspiration, or gentle curettage. We prefer hydrodissection to flush out the gestational products, as it helps to ascertain complete removal of trophoblast.",
"   </p>",
"   <p>",
"    Successful hysteroscopic removal of interstitial ectopic pregnancy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The efficacy and long-term results of this technique are unknown.",
"   </p>",
"   <p>",
"    The possibility of uterine rupture during a subsequent pregnancy should be discussed with women undergoing treatment for interstitial pregnancy. Unfortunately, the risk of uterine rupture after medical treatment of an interstitial pregnancy is unknown and the integrity of the uterus following conservative surgical treatment is unclear, although cases of uterine rupture have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Multilayered suturing of the myometrium and serosa of the uterine cornua following conservative surgical treatment may prevent this complication.",
"   </p>",
"   <p>",
"    Close antenatal monitoring of women with a history of interstitial pregnancy is mandatory. We suggest scheduling a cesarean delivery at term to avoid the risk of uterine rupture during labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OUTCOME AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Persistent ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of persistent ectopic pregnancy reported in case series ranges from 4 to 15 percent, and, as noted above, is generally higher after laparoscopic salpingostomy than after open procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clearance rate of serum beta-hCG following salpingostomy is similar to that after salpingectomy. One study found that the serum beta-hCG concentration on the first postoperative day generally declined by more than 50 percent of the preoperative value [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/32\">",
"     32",
"    </a>",
"    ]. In this series of 147 women treated conservatively for ectopic pregnancy, there were no cases of persistent ectopic pregnancy when the postoperative beta-hCG on day 1 fell by more than 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts suggest weekly measurement of serum beta-hCG concentration after laparoscopic salpingostomy to look for women with persistent disease.",
"   </p>",
"   <p>",
"    Measurement of serum beta-hCG concentration is then performed weekly until the level is undetectable. In most cases, these measures are not needed.",
"   </p>",
"   <p>",
"    Alternatively, prophylactic treatment with one dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be given after all salpingostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/33\">",
"     33",
"    </a>",
"    ], limited to cases where the surgeon is not sure whether the entire products of conception have been removed.",
"   </p>",
"   <p>",
"    The reproductive outcome within three years of treatment of persistent ectopic pregnancy was illustrated in a review of 50 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 60 percent of women who attempted to conceive achieved an intrauterine pregnancy and there were no recurrent ectopic pregnancies. The pregnancy rate was comparable to that in women who were successfully treated for their primary ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic implantation usually occurs because clinical or subclinical salpingitis has caused anatomic and functional changes in the fallopian tubes. These changes are typically bilateral and permanent; thus, it is not surprising that ectopic pregnancy often leads to recurrent ectopic pregnancy and infertility.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrauterine pregnancy &mdash; In women with a history of ectopic pregnancy, review of observational data from a variety of patient populations and with varying durations of follow-up shows that 38 to 89 percent will achieve a subsequent intrauterine gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent ectopic pregnancy &mdash; The incidence of recurrent ectopic pregnancy is approximately 15 percent (range 4 to 28 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/31\">",
"       31",
"      </a>",
"      ]. In one review, recurrent ectopic pregnancy rate after salpingectomy was lower than after salpingostomy (9.9 versus 14.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/1\">",
"       1",
"      </a>",
"      ]. After",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      treatment, the recurrent ectopic rates range between 10.2 percent to 18.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. The differences could be related to the varied condition of the fallopian tubes. The recurrence risk rises to 30 percent following two ectopic pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As an example, a prospective study followed 328 women who were not using intrauterine contraception at the time of their ectopic pregnancy, and who subsequently tried to become pregnant [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/35\">",
"       35",
"      </a>",
"      ]. Cumulative outcomes after 12 months were: pregnancy rate (66 percent), intrauterine pregnancy rate (56 percent), ectopic pregnancy rate (13 percent), and live birth rate (31 percent). Maternal age greater than 35 years, history of infertility, and tubal damage were associated with decreased reproductive performance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many factors influence a woman's fertility after a tubal pregnancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of prior infertility is the most important factor for predicting subsequent fertility [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/38\">",
"       38",
"      </a>",
"      ]. The pregnancy rate following ectopic pregnancy in women with a history of infertility is one-fourth that of women without known infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prior tubal damage is associated with a decreased rate of future pregnancy compared to controls with normal appearing tubes (pregnancy rate 42 and 79 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/7\">",
"       7",
"      </a>",
"      ]. Ipsilateral periadnexal adhesions reflect poor condition of the tube [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Women who have an intrauterine contraceptive device at the time of their ectopic pregnancy appear to have a better prognosis for future fertility. Among 23 intrauterine contraception users, there was no recurrence of ectopic pregnancy, while 28 percent of 305 nonusers had recurrences in the following two years [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost all (93 percent) spontaneous pregnancies after surgical treatment of ectopic pregnancy occur in the first 18 months following the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5976/abstract/42\">",
"     42",
"    </a>",
"    ]. If the woman does not conceive in the first 12 to 18 months, or her contralateral tube is damaged or absent, referral for in vitro fertilization is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H874697\">",
"    <span class=\"h3\">",
"     Interval to conception",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are",
"    <strong>",
"     no",
"    </strong>",
"    data to establish the optimal interval to conception following surgical treatment of an ectopic pregnancy. In our practice, we advise patients that they may try to conceive again following their next menstrual period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF NONTUBAL ECTOPIC PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of cervical, abdominal, and cesarean scar pregnancies is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=see_link\">",
"     \"Cervical pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=see_link\">",
"     \"Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=see_link\">",
"       \"Patient information: Ectopic pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"       \"Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest surgical rather than medical therapy for women with ruptured ectopic pregnancy, contraindications to use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       inability/unwillingness",
"      </span>",
"      to comply with monitoring after medical therapy, lack of timely access to a medical institution for management of tubal rupture, failed medical therapy, and serum beta human chorionic gonadotropin (hCG) concentration greater than 5000",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      before treatment or fetal cardiac activity on ultrasonographic examination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention should only be considered if a transvaginal ultrasound examination clearly shows a tubal ectopic pregnancy or an adnexal mass suggestive of ectopic pregnancy. If no abnormality is imaged sonographically, there is a high probability that an ectopic pregnancy will not be visualized or palpated at surgery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women who are hemodynamically stable and appear to have a reasonable probability of future normal tubal function in the affected tube, we suggest salpingostomy rather than salpingectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Salpingostomy versus salpingectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest salpingectomy in the following situations: uncontrolled bleeding, recurrent ectopic pregnancy in the same tube, severely damaged tube, large tubal pregnancy (ie, greater than 5 cm), and women who have completed childbearing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend laparoscopic salpingostomy rather than an open surgical procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A disadvantage of laparoscopic salpingostomy is that it is associated with a higher rate of persistent trophoblast than open salpingostomy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laparoscopy versus laparotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent ectopic pregnancy after salpingostomy occurs in 4 to 15 percent of cases. We perform a single serum beta-hCG measurement one week after surgery. A level that is less than 5 percent of the preoperative value is consistent with complete resolution of the ectopic pregnancy; a higher value calls for repeat measurement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Persistent ectopic pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After an ectopic pregnancy, 38 to 89 percent of women will achieve a subsequent intrauterine gestation. Recurrent ectopic pregnancy occurs in 15 percent (range 4 to 28 percent); the recurrence risk rises to 30 percent following two ectopic pregnancies. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Outcome and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the woman does not conceive in the first 12 to 18 months after surgical therapy of ectopic pregnancy, or her contralateral tube is damaged or absent, referral for in vitro fertilization is appropriate. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Outcome and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/1\">",
"      Yao M, Tulandi T. Current status of surgical and nonsurgical management of ectopic pregnancy. Fertil Steril 1997; 67:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/2\">",
"      Hajenius PJ, Mol F, Mol BW, et al. Interventions for tubal ectopic pregnancy. Cochrane Database Syst Rev 2007; :CD000324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/3\">",
"      Murphy AA, Nager CW, Wujek JJ, et al. Operative laparoscopy versus laparotomy for the management of ectopic pregnancy: a prospective trial. Fertil Steril 1992; 57:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/4\">",
"      Vermesh M, Silva PD, Rosen GF, et al. Management of unruptured ectopic gestation by linear salpingostomy: a prospective, randomized clinical trial of laparoscopy versus laparotomy. Obstet Gynecol 1989; 73:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/5\">",
"      Lundorff P, Thorburn J, Hahlin M, et al. Laparoscopic surgery in ectopic pregnancy. A randomized trial versus laparotomy. Acta Obstet Gynecol Scand 1991; 70:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/6\">",
"      Bangsgaard N, Lund CO, Ottesen B, Nilas L. Improved fertility following conservative surgical treatment of ectopic pregnancy. BJOG 2003; 110:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/7\">",
"      Silva PD, Schaper AM, Rooney B. Reproductive outcome after 143 laparoscopic procedures for ectopic pregnancy. Obstet Gynecol 1993; 81:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/8\">",
"      Job-Spira N, Bouyer J, Pouly JL, et al. Fertility after ectopic pregnancy: first results of a population-based cohort study in france. Hum Reprod 1996; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/9\">",
"      Mol BW, Matthijsse HC, Tinga DJ, et al. Fertility after conservative and radical surgery for tubal pregnancy. Hum Reprod 1998; 13:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/10\">",
"      Dubuisson JB, Morice P, Chapron C, et al. Salpingectomy - the laparoscopic surgical choice for ectopic pregnancy. Hum Reprod 1996; 11:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/11\">",
"      Savaris RF, Cavazzola LT. Ectopic pregnancy: laparoendoscopic single-site surgery--laparoscopic surgery through a single cutaneous incision. Fertil Steril 2009; 92:1170.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/12\">",
"      Lee ES, Hahn HS, Park BJ, et al. Single-port laparoscopic cornual resection for a spontaneous cornual ectopic pregnancy following ipsilateral salpingectomy. Fertil Steril 2011; 96:e106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/13\">",
"      Lazard A, Poizac S, Courbiere B, et al. Cornual resection for interstitial pregnancy by laparoendoscopic single-site surgery. Fertil Steril 2011; 95:2432.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/14\">",
"      Bedaiwy MA, Escobar PF, Pinkerton J, Hurd W. Laparoendoscopic single-site salpingectomy in isthmic and ampullary ectopic pregnancy: preliminary report and technique. J Minim Invasive Gynecol 2011; 18:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/15\">",
"      Yoon BS, Park H, Seong SJ, et al. Single-port versus conventional laparoscopic salpingectomy in tubal pregnancy: a comparison of surgical outcomes. Eur J Obstet Gynecol Reprod Biol 2011; 159:190.",
"     </a>",
"    </li>",
"    <li>",
"     Tulandi, T. Tubal ectopic pregnancy: salpingostomy and salpingectomy. In: Atlas of Laparoscopy and Hysteroscopy Technique, Tulandi, T (Ed), W.B. Saunders, London 1999. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/17\">",
"      Tulandi T, Guralnick M. Treatment of tubal ectopic pregnancy by salpingotomy with or without tubal suturing and salpingectomy. Fertil Steril 1991; 55:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/18\">",
"      Fujishita A, Masuzaki H, Khan KN, et al. Laparoscopic salpingotomy for tubal pregnancy: comparison of linear salpingotomy with and without suturing. Hum Reprod 2004; 19:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/19\">",
"      Lau S, Tulandi T. Conservative medical and surgical management of interstitial ectopic pregnancy. Fertil Steril 1999; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/20\">",
"      Habana A, Dokras A, Giraldo JL, Jones EE. Cornual heterotopic pregnancy: contemporary management options. Am J Obstet Gynecol 2000; 182:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/21\">",
"      Moon HS, Choi YJ, Park YH, Kim SG. New simple endoscopic operations for interstitial pregnancies. Am J Obstet Gynecol 2000; 182:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/22\">",
"      Moawad NS, Mahajan ST, Moniz MH, et al. Current diagnosis and treatment of interstitial pregnancy. Am J Obstet Gynecol 2010; 202:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/23\">",
"      Tulandi T, Al-Jaroudi D. Interstitial pregnancy: results generated from the Society of Reproductive Surgeons Registry. Obstet Gynecol 2004; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/24\">",
"      Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril 1989; 51:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/25\">",
"      Jermy K, Thomas J, Doo A, Bourne T. The conservative management of interstitial pregnancy. BJOG 2004; 111:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/26\">",
"      Soriano D, Vicus D, Mashiach R, et al. Laparoscopic treatment of cornual pregnancy: a series of 20 consecutive cases. Fertil Steril 2008; 90:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/27\">",
"      Meyer WR, Mitchell DE. Hysteroscopic removal of an interstitial ectopic gestation. A case report. J Reprod Med 1989; 34:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/28\">",
"      Budnick SG, Jacobs SL, Nulsen JC, Metzger DA. Conservative management of interstitial pregnancy. Obstet Gynecol Surv 1993; 48:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/29\">",
"      Weissman A, Fishman A. Uterine rupture following conservative surgery for interstitial pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 44:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/30\">",
"      Downey GP, Tuck SM. Spontaneous uterine rupture during subsequent pregnancy following non-excision of an interstitial ectopic gestation. Br J Obstet Gynaecol 1994; 101:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/31\">",
"      Farquhar CM. Ectopic pregnancy. Lancet 2005; 366:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/32\">",
"      Spandorfer SD, Sawin SW, Benjamin I, Barnhart KT. Postoperative day 1 serum human chorionic gonadotropin level as a predictor of persistent ectopic pregnancy after conservative surgical management. Fertil Steril 1997; 68:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/33\">",
"      Gracia CR, Brown HA, Barnhart KT. Prophylactic methotrexate after linear salpingostomy: a decision analysis. Fertil Steril 2001; 76:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/34\">",
"      Seifer DB, Silva PD, Grainger DA, et al. Reproductive potential after treatment for persistent ectopic pregnancy. Fertil Steril 1994; 62:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/35\">",
"      Ego A, Subtil D, Cosson M, et al. Survival analysis of fertility after ectopic pregnancy. Fertil Steril 2001; 75:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/36\">",
"      Gervaise A, Masson L, de Tayrac R, et al. Reproductive outcome after methotrexate treatment of tubal pregnancies. Fertil Steril 2004; 82:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/37\">",
"      Tulandi T. Reproductive performance of women after two tubal ectopic pregnancies. Fertil Steril 1988; 50:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/38\">",
"      Ory SJ, Nnadi E, Herrmann R, et al. Fertility after ectopic pregnancy. Fertil Steril 1993; 60:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/39\">",
"      Sultana CJ, Easley K, Collins RL. Outcome of laparoscopic versus traditional surgery for ectopic pregnancies. Fertil Steril 1992; 57:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/40\">",
"      Pouly JL, Chapron C, Manhes H, et al. Multifactorial analysis of fertility after conservative laparoscopic treatment of ectopic pregnancy in a series of 223 patients. Fertil Steril 1991; 56:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/41\">",
"      Bernoux A, Job-Spira N, Germain E, et al. Fertility outcome after ectopic pregnancy and use of an intrauterine device at the time of the index ectopic pregnancy. Hum Reprod 2000; 15:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5976/abstract/42\">",
"      Dubuisson JB, Aubriot FX, Foulot H, et al. Reproductive outcome after laparoscopic salpingectomy for tubal pregnancy. Fertil Steril 1990; 53:1004.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3306 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5976=[""].join("\n");
var outline_f5_53_5976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALTERNATIVES TO SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SURGICAL PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Salpingostomy versus salpingectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laparoscopy versus laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Procedure for laparoscopic salpingostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Procedure for laparoscopic salpingectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Procedure for open salpingectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cornuostomy or cornual resection of interstitial pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OUTCOME AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Persistent ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H874697\">",
"      - Interval to conception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF NONTUBAL ECTOPIC PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3306|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/1/15380\" title=\"figure 1\">",
"      Linear salpingostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/13/3283\" title=\"figure 2\">",
"      Mesosalpingeal vessel ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/52/27461\" title=\"figure 3\">",
"      Laparoscopic salpingectomy caut",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/57/26516\" title=\"figure 4\">",
"      Laparoscopic salpingectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/47/28400\" title=\"figure 5\">",
"      Salpingectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/13/25808\" title=\"figure 6\">",
"      Resection interstitial pregnanc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/4/16457?source=related_link\">",
"      Abdominal pregnancy, cesarean scar pregnancy, and heterotopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11062?source=related_link\">",
"      Cervical pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21444?source=related_link\">",
"      Expectant management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=related_link\">",
"      Laparoendoscopic single-site (single port) surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27417?source=related_link\">",
"      Methotrexate treatment of tubal and interstitial ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=related_link\">",
"      Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/20/35138?source=related_link\">",
"      Patient information: Ectopic pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_53_5977="Perioral dermatitis";
var content_f5_53_5977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73779%7EDERM%2F64577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73779%7EDERM%2F64577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple acneiform papules can be seen on this young woman. Note the characteristic sparing around the lips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clustered small papules are present on the perioral skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5977=[""].join("\n");
var outline_f5_53_5977=null;
var title_f5_53_5978="Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis";
var content_f5_53_5978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/53/5978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5978/contributors\">",
"     Scott K Heysell, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5978/contributors\">",
"     Gerald Friedland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/53/5978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5978/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/53/5978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/53/5978/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/53/5978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multi-drug resistant (MDR) tuberculosis has emerged in epidemic proportions in the wake of widespread HIV infection among the world's poorest populations, including sub-Saharan Africa. Extensively drug-resistant tuberculosis (XDR TB) was first reported in 2006 and has now been documented on six continents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"     1",
"    </a>",
"    ]. These trends are critically important for global health since the mortality from drug-resistant TB is high, and second and third-line therapeutic agents are less potent and tolerable than first-line therapies.",
"   </p>",
"   <p>",
"    This topic will focus specifically on the clinical manifestations, diagnosis, treatment, and prevention of XDR TB. The epidemiology of XDR drug resistance is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34743?source=see_link\">",
"     \"Epidemiology of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Information on MDR TB, drug-susceptible TB, and the diagnosis of drug-susceptible tuberculosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDR TB is defined as laboratory-confirmed resistance to the two most potent first-line medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/2\">",
"     2",
"    </a>",
"    ]. XDR TB is defined as resistance to both isoniazid and rifampin with additional resistance to at least one fluoroquinolone and one injectable agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of XDR TB are indistinguishable from those of drug-susceptible TB. There are currently no symptoms, signs, exam findings, radiographic or laboratory tests that have been validated to differentiate XDR TB from other less-resistant types of TB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to consider the possibility of drug-resistant disease whenever prescribing antituberculous medications. Ongoing treatment in the face of drug resistance can lead to significant morbidity and mortality and amplify further drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prior to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain demographic and historical features may raise suspicion of drug-resistant tuberculosis, including previous treatment for TB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/5\">",
"     5",
"    </a>",
"    ], local rates of drug resistance, or contact with a patient with known drug resistance. A cross-sectional study in Estonia, a country with one of the world's highest rates of XDR TB, also identified HIV infection, homelessness, and a history of alcohol abuse as predictors of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients in whom prior antituberculosis therapy has been prescribed, the physician must obtain a complete record of all previous cultures, drug susceptibility testing results, and past drug exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     During treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug resistance is clinically suspected when patients fail to respond to standard first-line TB regimens. This may be inferred by lack of clinical improvement or when a patient's sputum AFB smear remains persistently positive after two months of therapy (",
"    <a class=\"graphic graphic_picture graphicRef56964 \" href=\"UTD.htm?36/51/37680\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34743?source=see_link\">",
"     \"Epidemiology of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of TB is made clinically and with the laboratory support of either culture-based methods or rapid diagnostic techniques. Detailed information on the various assays for the diagnosis of drug-resistant TB is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plating on agar or liquid media for drug susceptibility testing for second-line drugs remains the gold standard for XDR TB diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/6\">",
"     6",
"    </a>",
"    ]. While some rapid molecular diagnostic tools for second-line drugs are commercially available [in the form of line-probe assays for gyrA resistance mutations for fluoroquinolones, and rrs resistance mutations for injectable agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    and to a lesser extent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    )] [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/7\">",
"     7",
"    </a>",
"    ], the sensitivity of these assays is lower than the sensitivity of rapid diagnostic assays for mutations conferring resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-seropositive patients have higher rates of extrapulmonary disease and smear-negative pulmonary disease, which makes diagnosis by sputum particularly insensitive. Aspiration of lymph node and pleural fluid, as well as mycobacterial blood culture, have been of additive yield in diagnosing MDR and XDR TB in predominately HIV-infected cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More rapid and more reliable laboratory diagnostics for XDR TB are urgently needed, given the high mortality rate, the lack of distinguishing clinical features, and the risk of transmission to others in the absence of definitive treatment. Given the lag time for culture and drug-susceptibility testing, many patients die before the laboratory diagnosis of XDR TB is confirmed. For example, in the case series involving 53 patients with XDR TB from rural Tugela Ferry, South Africa, the median survival from the time of sputum collection for TB culture was 16 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Costly technologies that require an upgrade in laboratory personnel or facilities are usually not feasible in resource-limited settings. Therefore, diagnostic approaches are urgently needed for XDR TB that may be offered close to the point of care. Simplification of molecular-diagnostic techniques, rapid-liquid culture, and the use of colorimetric indicators are being developed to improve the sensitivity, speed, and reliability of drug-resistant tuberculosis detection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HIV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with suspected or confirmed TB should be offered voluntary counseling and testing for HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     AVAILABLE DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many drugs available for TB, which can be categorized by potency and efficacy. Most of these drugs will not be effective in the treatment of XDR TB because of drug resistance and many have not been formally studied for the treatment of drug-resistant TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     First-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, XDR TB isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and are frequently resistant to other oral first-line agents as well, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    . Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , a first-line injectable agent, is also commonly present.",
"   </p>",
"   <p>",
"    In a patient with drug-resistant TB, any remaining first-line agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , should only be employed if drug susceptibility testing is favorable. If the XDR TB isolate is susceptible to ethambutol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pyrazinamide, these medications are often continued for the entire course of therapy, unlike in drug-susceptible TB, where pyrazinamide is only used for the first two months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the results of drug susceptibility testing, second-line oral agents that may be of use include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thionamides (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      , prothionamide)",
"     </li>",
"     <li>",
"      Serine analogues (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      , terizidone, thiacetazone)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15141?source=see_link\">",
"       Para-aminosalicylic acid",
"      </a>",
"      (PAS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Later generation fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) have also been used in the treatment of XDR TB despite the existence, by definition, of fluoroquinolone resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/14\">",
"     14",
"    </a>",
"    ]. This strategy continues to be debated (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment for documented XDR TB'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24\">",
"     'Therapeutic pitfalls'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Cross-resistance'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Second-line injectable agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aminoglycosides (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"       Capreomycin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adverse events associated with use of these agents are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18375?source=see_link\">",
"     \"Second-line antituberculous therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Third-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third-line agents have lower overall potency and limited efficacy data. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       Linezolid",
"      </a>",
"     </li>",
"     <li>",
"      Clofazimine",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"     </li>",
"     <li>",
"      Meropenem-clavulanate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    has been is used in salvage cases; reports suggest clinical efficacy despite limited in vitro tuberculocidal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment for documented XDR TB'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Novel medications for the treatment of drug-resistant TB have reached later stages of development and include nitroimidazoles, diarylquinolines, and oxazolidinone derivatives [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Further clinical studies with specific application to XDR TB are eagerly anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few controlled trials upon which to base strong recommendations for the pharmacotherapy of XDR TB; practice is guided largely by case series, case controlled studies, and expert consensus.",
"   </p>",
"   <p>",
"    In general, the treatment of XDR TB should be carried out at specialty referral centers, since little systematic data exist on treatment strategies. The burden of XDR TB is anticipated to grow; therefore organized treatment trials, particularly in patients coinfected with XDR TB and HIV, are urgently needed.",
"   </p>",
"   <p>",
"    The following clinical studies in HIV-seronegative patients demonstrate the complexity of patient management issues.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 651 Peruvian patients with a history of treatment failure or relapse, 48 (7.4 percent) were identified as having XDR TB, while the rest of the patients had MDR TB [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"       1",
"      </a>",
"      ]. The initial isolates tested were resistant to an average of 8.4 agents in the XDR TB patients compared with 5.3 agents in the MDR TB patients out of the possible 12 agents that were evaluated.",
"      <br/>",
"      <br/>",
"      Under daily supervised therapy, an average of 5.3 drugs was dispensed to the patients with XDR TB; these medications were selected based on documented drug susceptibility or a history of minimal prior exposure. Most regimens included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      , PAS, and an injectable drug. Most patients also received a fluoroquinolone, despite documented resistance; however, testing for fluoroquinolone resistance was performed via a standard proportion-based method, where critical cut-offs were less well defined.",
"      <br/>",
"      <br/>",
"      Almost all of these patients also received two or more of the following:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"       rifabutin",
"      </a>",
"      , and clofazimine. The following observations were made:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The median time for sputum conversion was longer in patients with XDR TB than for those with MDR TB (90 versus 61 days; HR 0.63 95% CI 0.45-0.89).",
"     </li>",
"     <li>",
"      Cure rates among those with XDR TB were comparable to others who had MDR TB (approximately 60 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 211 HIV-seronegative patients in South Korea with drug-resistant TB, the XDR TB patients were treated for a longer duration (ie, 43 versus 25 months) and with a higher median number of drugs (ie, seven versus six). A higher proportion of patients with XDR TB also underwent surgical resection compared with those with MDR TB (ie, 56 versus 23 percent).",
"      <br/>",
"      <br/>",
"      However, a trend towards higher rates of treatment failure was seen among the 43 patients who had XDR TB than among the rest of the cohort (44 versus 27 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/19\">",
"       19",
"      </a>",
"      ]. This may have been partially related to recycling of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and rifamycins in greater than 40 percent of the XDR TB patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, empiric therapy for XDR TB is not well studied and the treatment approach may vary greatly based on regional resistance patterns and availability of second-line medications.",
"   </p>",
"   <p>",
"    XDR TB may be suspected in the following clinical scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical failure in a patient with a known XDR TB contact who is taking therapy for drug-susceptible TB",
"     </li>",
"     <li>",
"      Persistently positive sputum microscopy despite MDR TB therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these scenarios, we prefer to add the following drugs to the existing four-drug regimen while waiting for results of drug susceptibility testing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An injectable agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      ) if the patient is not already on an injectable medication",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      One or two oral second-line medications (eg, PAS and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      )",
"      <br/>",
"      PLUS",
"     </li>",
"     <li>",
"      A third-line agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later generation fluoroquinolone may also be empirically added based on regional drug susceptibility patterns. This may require that seven or more drugs be given until drug susceptibility results are obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT FOR DOCUMENTED XDR TB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for drug-resistant TB should be tailored for the individual patient based on drug susceptibility, potency, and toxicity, whenever possible.",
"   </p>",
"   <p>",
"    Within any given patient infected with M. tuberculosis, there is a varied population of organisms, each with naturally occurring resistance to a given medication that preexists prior to treatment. This observation mandates multi-drug therapy in order to decrease the risk of drug resistance. Regimens for drug-resistant TB usually include four to five drugs (including one injectable), and are administered in daily supervised schedules [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive randomized or controlled studies have not been performed to establish optimum regimens for treating patients with the various patterns of drug-resistant tuberculosis; thus, treatment recommendations are based on expert opinion. The principle of multidrug therapy is based on early clinical studies of drug-sensitive TB, which demonstrated that a three-drug therapy (during the initial phase of treatment) with first-line bactericidal agents (eg, INH and RIF) led to higher efficacy and enabled a shorter duration of therapy compared with two-drug therapy administered for the entire treatment period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, early studies of patients with TB resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    alone demonstrated that six months of therapy was no longer adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/22\">",
"     22",
"    </a>",
"    ]. This observation highlights the importance of bactericidal drugs for TB eradication. Thus, for suspected drug-resistant TB, it is important to include more agents for a longer period of time since many second and third-line agents are only bacteriostatic. Furthermore, reliable drug susceptibility testing is not available for all medications that are employed for XDR TB, thus requiring empiric addition of certain drugs.",
"   </p>",
"   <p>",
"    Drugs that are found to be resistant should be promptly discontinued since they would not be expected to be effective and may lead to additional toxicity.",
"   </p>",
"   <p>",
"    All oral agents are continued for the duration of therapy. The optimal duration for an injectable agent is unknown; a minimum of six months is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/20\">",
"     20",
"    </a>",
"    ], but many practitioners would urge extending an injectable agent for at least six months beyond the date of sputum culture conversion, or for the duration of the treatment course, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/23\">",
"     23",
"    </a>",
"    ]. This therapeutic decision must be weighed against medication toxicities, injection site reactions, and concerns for poor adherence when a patient is averse to the injectable agent (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Cross-resistance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Injectable agents'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Use of oral first-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for XDR TB should include any first-line medications to which the patient's organism is susceptible, whenever possible (see",
"    <a class=\"local\" href=\"#H10\">",
"     'First-line agents'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use of oral second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to reach the goal of at least four active antituberculosis agents, one or more oral second-line agents are employed; we prefer a thionamide (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    , prothionamide) based on tolerability. However, the same genetic mutations present in many",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    -resistant organisms can also lead to ethionamide resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/24\">",
"     24",
"    </a>",
"    ]. In a large TB screening study of HIV-infected patients in South Africa, 40 percent of those with MDR TB were also ethionamide resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/25\">",
"     25",
"    </a>",
"    ]. Ethionamide must therefore be used with caution in any empiric regimen for MDR or XDR TB.",
"   </p>",
"   <p>",
"    Within the serine analog category, terizidone is the preferred agent due to the neuropsychiatric side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    and the lower potency of thiacetazone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/20,26,27\">",
"     20,26,27",
"    </a>",
"    ]. Furthermore, thiacetazone is contraindicated in HIV-infected patients, given the high rates of Stevens-Johnson syndrome in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When three oral second-line agents are necessary, PAS is often employed. A later generation fluoroquinolone is also an attractive option since it is well tolerated, but concerns of cross-resistance persist (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Cross-resistance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26\">",
"     'Fluoroquinolones'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Many of these second-line agents are associated with significant gastrointestinal intolerance; PAS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    are all better tolerated with twice-daily dosing. Enteric coated PAS formulations are available at certain treatment facilities and are more tolerable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Use of third-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on efficacy of third-line agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , clofazimine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , meropenem-clavulanate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) for the treatment of XDR TB. However, third-line agents have been employed in patients with extensive drug resistance or intolerance based on their documented in vitro activity against M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    has been observed to be effective at achieving culture conversion among 38 HIV-negative patients with refractory XDR TB in South Korea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients continued their current regimen and were randomized to the addition of linezolid (600 mg daily) immediately or following a two-month delay. Following sputum culture conversion or four months of treatment with linezolid, patients underwent a second randomization to either continue linezolid at 600 mg daily or reduce the dose to 300 mg daily. Sputum culture conversion was achieved among 79 percent of patients in the immediate-start group and 35 percent of patients in the delayed-start group (p = 0.001). In both groups, culture conversion was achieved at six months of therapy among 89 percent of patients.",
"   </p>",
"   <p>",
"    Adverse events attributable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    occurred in 82 percent of patients but resolved quickly in most cases. Permanent discontinuation of linezolid was required in three cases due to toxicity (optic neuropathy in two and anemia in one). The likelihood of adverse drug event was 2.7 times more likely among patients receiving the higher linezolid dose (600 mg daily) following the second randomization than among patients receiving the lower linezolid dose (300 mg) (p = 0.03). Acquired drug resistance to linezolid was observed in 11 percent of cases, including 3 patients receiving the lower linezolid dose (300 mg daily) following the second randomization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the similarity in the signs and symptoms of drug-susceptible and drug-resistant disease, similar markers of clinical improvement are expected as well. However, in a patient with XDR TB, signs of clinical improvement may be slower as a result of the inability to use the most potent antituberculosis medications and the often longer duration of illness prior to treatment initiation. Clinical observation suggests that appetite returns early and weight loss stabilizes. Cough and chest x-ray improvement may lag behind other markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Sputum cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of XDR TB have used monthly sputum cultures and drug-susceptibility testing to monitor response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. In patients with extensive pulmonary disease, monthly or biweekly chest x-rays may also be monitored to gauge closely for radiographic signs of further treatment failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to prompt consideration of adjunctive surgery.",
"   </p>",
"   <p>",
"    Following two successive months of negative sputum cultures, repeat culture and drug-susceptibility testing are usually reserved only for persistent or worsening symptoms despite adequate adherence to therapy. Information regarding treatment monitoring is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Drug susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug susceptibility testing (DST) should accompany all sputum cultures in drug-resistant patients, assuming it is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     THERAPEUTIC PITFALLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;General treatment principles dictate that a single agent should never be added to a failing regimen in patients with suspected drug-resistant tuberculosis because of the risk of fostering further drug resistance. However, a concept of \"regimen reinforcement\" has been advocated, and argues that additional agents should be added to the regimen of a patient with confirmed drug-resistant tuberculosis who has persistently positive sputum microscopy after several months of treatment (eg, three months). In this circumstance, there are no other viable four or five-drug combination regimens that can be given. Thus, any remaining effective agents may be added, or current agents switched, based on the latest drug resistance testing pattern.",
"   </p>",
"   <p>",
"    Regimen reinforcement should only be employed as a last resort to control the patient's infection when there are no viable alternatives. In this clinical scenario, it is hoped that the burden of organisms has declined and that the risk of developing further resistance may be lower than during the initial presentation of disease.",
"   </p>",
"   <p>",
"    Third-line agents have been used for reinforcement strategies in patients failing to improve on XDR TB treatment. For instance, in the Peruvian cohort noted above, one-third of the patients had persistently positive sputum cultures for XDR TB at four months; regimen adjustments included changing to a later generation fluoroquinolone,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adding one or more third-line agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , or clofazimine) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"     1",
"    </a>",
"    ]. Yet it is important to note that acquired resistance has been described among patients with chronic XDR TB treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Use of third-line agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CROSS-RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug susceptibility panels may not be available for all TB medications; thus, it is important to understand common patterns of cross-resistance when using second-line agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fluoroquinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, a patient with XDR TB will have resistance to at least one of the fluoroquinolones. Yet, there remains controversy about the degree of cross-resistance and effectiveness of individual agents within this class. There are also conflicting data as to whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    demonstrate better in vitro efficacy than older generation fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/23\">",
"     23",
"    </a>",
"    ]. One research laboratory found complete cross-resistance among all members of the fluoroquinolone family through standard agar preparation methods and rapid testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/31\">",
"     31",
"    </a>",
"    ]. Unfortunately, many laboratories do not possess the capability of testing TB isolates against multiple types of fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avoidance of the entire class has been practiced in certain centers, while others have used fluoroquinolones in all patients diagnosed with XDR TB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1,23,33\">",
"     1,23,33",
"    </a>",
"    ]. No data from randomized trials are available to guide the use of these agents. However, a meta-analysis examining TB treatment outcomes among 560 patients from 13 observational studies suggested that fluoroquinolone administration was associated with more favorable clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Injectable agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the TB isolate is susceptible,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    are the best choices for an injectable agent. Notably, there may be nearly 100 percent cross-resistance between amikacin and kanamycin in some settings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/32,34\">",
"     32,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"     capreomycin",
"    </a>",
"    and the aminoglycosides may have different susceptibilities; furthermore, capreomycin can be used in the patient with renal insufficiency. In the Peruvian cohort of XDR TB patients, 52 percent of patients were able to receive capreomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"     1",
"    </a>",
"    ]. However, capreomycin use does require close monitoring for its propensity to cause hypokalemia. In an alert issued from a TB referral hospital in KwaZulu-Natal, South Africa, 20 of 62 patients (32 percent) died during treatment for XDR TB; five of these patients died from hypokalemia related to capreomycin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of therapy often extends for an average of 18 months after sputum conversion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1,19,36\">",
"     1,19,36",
"    </a>",
"    ]. The extent of the patient's disease, microbiological resistance pattern, the speed of conversion to a negative sputum culture, and tolerance to medications determine a given patient's course.",
"   </p>",
"   <p>",
"    These principles are best illustrated with case histories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An HIV-seronegative patient has pulmonary tuberculosis confined to one lobe of a lung. A drug resistance panel demonstrates resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , rifampicin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      ; however, the isolate is susceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      . We typically will combine pyrazinamide and ethambutol with one or two oral second-line medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      and terizidone) and one injectable agent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      . We would begin monthly monitoring of sputum cultures and would treat with capreomycin for six months after sputum conversion. Assuming symptoms and radiologic changes are consistent with overall clinical improvement, the remaining oral medications would be given for 12 months following discontinuation of capreomycin (eg, 18 months after sputum conversion).",
"     </li>",
"     <li>",
"      An HIV-seropositive patient with a CD4 cell count of 65",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      has miliary disease of the lungs, a pericardial effusion, splenic granulomata, and extensive periaortic lymphadenopathy. Drug susceptibility testing demonstrates resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , rifampicin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      . When faced with extensive drug resistance such as this, we typically will construct an antituberculosis regimen of oral second-line (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      , terizidone, and PAS) and third-line medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or, if available,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      or a later generation fluoroquinolone such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ) along with early initiation of antiretroviral therapy (within two weeks). The overall prognosis in this clinical scenario is usually poor, but if the patient tolerates this complex regimen, we prefer to treat with an oral TB regimen for an additional 18 months after attaining immunologic recovery (eg, CD4 count rise of 100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      in first year). This may equate to a total treatment duration of three years; however, the duration of treatment takes on greater importance when the number of effective drugs is limited and the host has advanced immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TREATMENT OF HIV-INFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment regimens for XDR TB in HIV-positive patients require special attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Initiation of ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data in patients with drug-susceptible TB demonstrate that a low CD4 count is associated with high early mortality at the start of therapy and is most dramatic during the first three months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/37\">",
"     37",
"    </a>",
"    ]. Mortality rates after this timepoint remain stable and are similar to those seen in resource-rich countries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient is not yet receiving treatment for HIV, the diagnosis of drug-resistant TB necessitates the initiation of ART. However, a decision must be made regarding the timing of ART after the patient has commenced antituberculosis therapy. This issue has been studied in large randomized controlled trials among patients with drug-susceptible TB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Until further data are available, it is appropriate to follow the 2012 US Department of Health and Human Services guidelines for HIV treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with pulmonary TB and HIV with advanced immunosuppression (CD4 &lt;50)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      debilitation (low Karnofsky score), ART should be initiated within two weeks of starting TB treatment.",
"     </li>",
"     <li>",
"      In patients with CD4 &ge;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      but with severe disease (based on low Karnofsky score, low body mass index [BMI], low hemoglobin, low albumin, or organ system dysfunction) ART should be initiated within two to four weeks of starting TB treatment.",
"     </li>",
"     <li>",
"      In patients with less severe disease and CD4 &ge;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      ART should be delayed to 8 to 12 weeks of TB treatment. In the absence of similar randomized control trials, the high mortality associated with XDR TB and HIV coinfection has led experts to favor early ART initiation, regardless of CD4 count.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likely decreased mortality from early initiation of ART in coinfected patients with XDR TB must be balanced against the additive toxicities of HIV and TB medications, risk of immune reconstitution syndrome, and decreased adherence when many medications are given concomitantly. For example, if one considers cotrimoxazole prophylaxis and a multivitamin, an HIV-infected patient with drug-resistant TB may be taking up to 12 different medications at one time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of ART in of the setting of TB meningitis also remains unresolved, and greater caution for morbidity and mortality related increased intracranial pressure due to immune reconstitution must be considered.",
"   </p>",
"   <p>",
"    In a retrospective study of 129 HIV-infected patients in South Africa with XDR TB at 180 days following diagnosis, survivors were more likely in multivariate analyses to have had negative initial AFB smears, an absence of laboratory markers indicative of multiorgan dysfunction, a CD4 count &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    and to have received antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/44\">",
"     44",
"    </a>",
"    ]. Therefore survival in patients coinfected with HIV and XDR TB may be improved by modifiable factors of both diseases (",
"    <a class=\"graphic graphic_figure graphicRef85867 \" href=\"UTD.htm?4/8/4224\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Drug interactions and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies are also needed to clarify the pharmacokinetic and pharmacodynamic interactions between antiretroviral agents and second-line agents for drug-resistant TB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Notable toxicities and potential drug interactions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuropsychiatric effects associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      use",
"     </li>",
"     <li>",
"      Peripheral neuropathy associated with both aminoglycosides and the nucleoside reverse transcriptase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"     </li>",
"     <li>",
"      Gastrointestinal side effects, which are common with many protease inhibitors and many of the second-line agents for TB (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"       ethionamide",
"      </a>",
"      and PAS) (",
"      <a class=\"graphic graphic_table graphicRef53563 \" href=\"UTD.htm?25/52/26444\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Immune reconstitution syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune reconstitution inflammatory syndrome (IRIS) refers to a \"paradoxical\" worsening or recurrence of symptoms, signs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiologic manifestations of TB, which can occur after the initiation of ART. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no diagnostic tests for TB-associated IRIS and the differential diagnosis of this syndrome is wide, including failure of TB treatment attributable to antimicrobial resistance, suboptimal antitubercular drug concentrations, drug reactions, or other opportunistic infections. In one prospective cohort of 100 patients with suspected TB IRIS in Cape Town, South Africa, seven patients were diagnosed with an alternate opportunistic infection and seven had MDR TB, which were clinically indistinguishable from IRIS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/48\">",
"     48",
"    </a>",
"    ]. These results support the view that a clinical assessment of TB-associated IRIS should include evaluation for other opportunistic infections and testing for TB drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that IRIS may be more pronounced in patients with known drug-resistant TB who are initiating ART, but further study is warranted in a cohort of coinfected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     RESECTIVE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical debulking of areas of pulmonary cavitation and localized disease has been advocated as an adjunct to medical therapy. In a carefully selected population of HIV-negative patients, resective surgery (lobectomy, wedge resection, or pneumonectomy) can help achieve relatively rapid sputum culture conversion and provide durable cure in patients with both MDR and XDR TB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1,50-52\">",
"     1,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical therapy is started prior to resective surgery in most cases. In the cohort of patients with XDR TB from Peru, 7 of 48 (14.6 percent) underwent some form of resective surgery, but did so at a median of 11.6 months after the initiation of medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients undergoing surgery were also treated with medical therapy for a median of 6.3 months longer than the cohort as a whole.",
"   </p>",
"   <p>",
"    In HIV-seronegative patients from a specialty hospital in South Korea, MDR and XDR TB patients with localized disease had resective surgery performed after a median duration of 8.5 months of medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/50\">",
"     50",
"    </a>",
"    ]. Not only was cure achieved in 15 of 19 patients, but these patients were also able to switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and rifampicin-based regimens. This remarkable achievement centers on the pathophysiologic observation that in acquired drug-resistant TB, the majority of bacilli that have evaded immunologic and pharmacologic attack reside on the surface of tuberculous cavities within the lung. Surgical resection of disease confined to these spaces removes the bulk of drug-resistant TB bacilli leaving behind only microscopic populations of largely drug-susceptible TB [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This practice may NOT be applicable to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who were infected with an XDR TB strain during primary transmission, as they are unlikely to have any drug-susceptible TB present",
"     </li>",
"     <li>",
"      HIV-infected patients with extrapulmonary disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further research is needed regarding the selection of surgical candidates, timing of surgery, optimal medication regimens, and duration of therapy following surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment outcomes for XDR TB are generally worse compared with those for drug-susceptible TB, partly because second-line medications are less potent and more toxic than first-line medications. In addition, many second-line medications are not available in resource-limited settings where XDR TB is prevalent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the WHO's Green Light Committee, in association with the Global Fund to Fight AIDS, Tuberculosis and Malaria, has recently developed a system to improve access to second-line medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     HIV status and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among HIV-seronegative patients, survival rates are poor, ranging from 48 to 60 percent in cohorts from South Korea, Russia, and Peru [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/1,19,36\">",
"     1,19,36",
"    </a>",
"    ]. However, most studies suggest that HIV status correlates with poorer outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In XDR TB cases reported from the United States, there was an overall 35 percent mortality, but mortality was 81 percent in the subset of HIV-seropositive patients (",
"      <a class=\"graphic graphic_table graphicRef51301 \" href=\"UTD.htm?7/44/7886\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the original case series from Tugela Ferry, South Africa, the mortality rate among those identified with both HIV and XDR TB infection was 98 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/12\">",
"       12",
"      </a>",
"      ]. In subsequent analysis of 139 patients with XDR TB, 80 percent died. Factors significantly associated with mortality included CD4 count &le;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and resistance to all six anti-TB drugs tested; use of ART was protective [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, in a retrospective study of 227 patients with XDR TB in South Africa (82 of whom were HIV-seropositive), the number of deaths did not differ significantly between HIV-seropositive and HIV-seronegative patients (41 percent versus 30 percent); ART use (mostly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ) was protective [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the overall prognosis for adults with XDR TB is poor with high rates of mortality; delays in diagnosis and extent of drug-resistance, malnutrition, and advanced immunosuppression contribute to an increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extensively drug-resistant tuberculosis (XDR TB) was first reported in 2006 and has been documented in 57 countries in all regions of the world with notable foci in sub-Saharan Africa, Eastern Europe, and countries of the former Soviet Union. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of XDR TB are indistinguishable from disease secondary to susceptible isolates. However, patients with XDR TB are at increased risk for disseminated disease, slower rates of sputum conversion, and increased mortality compared with patients with MDR TB or susceptible isolates [",
"      <a class=\"abstract\" href=\"UTD.htm?5/53/5978/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently mycobacterial culture with secondary drug susceptibility testing (DST) is the most reliable means of laboratory confirmation of XDR TB, a process that can take up to three months. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outcomes are generally poor for adults with XDR TB, with cure rates at best of 60 percent in HIV-negative patients and mortality rates as high as 98 percent in HIV-positive patients. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many countries employ non-individualized regimens, which are based on regional drug susceptibility patterns, while awaiting drug susceptibility test results in patients with suspected TB. This may require that six or more drugs be given until drug susceptibility results are obtained. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for documented XDR TB should include any first-line medications to which the isolate is susceptible. We recommend regimens that include five drugs or more, with at least one injectable agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Of the third-line agents to be used when resistance or drug availability precludes the use of other second-line agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      may have particular benefit but must be balanced with the considerable toxicity of long-term use and further amplification of drug resistance. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment for documented XDR TB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an HIV-seronegative patient, the duration of therapy often extends for an average of 18 months after sputum conversion. In an HIV-infected patient, we prefer to continue treatment for 18 months after achieving a stable immunological response on ART (eg &gt;100",
"      <span class=\"nowrap\">",
"       cell/microL",
"      </span>",
"      increase). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resective surgery (lobectomy, wedge resection, or pneumonectomy) can help a patient attain sputum conversion and improve chances of full recovery in patients with localized drug-resistant pulmonary TB. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Resective surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of HIV-infected patients with XDR TB is complex. Antiretroviral therapy (ART) is essential and is associated with improved outcomes among coinfected patients. Studies in drug-susceptible pulmonary TB and HIV support initiation of ART at two weeks of therapy in those with CD4 &lt;50",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced disease or multiorgan system dysfunction. The pharmacokinetic and pharmacodynamic interactions between antiretroviral agents and second-line TB medications require further study, as does assessment of additive side effects and toxicities. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Treatment of HIV-infected patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/1\">",
"      Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/2\">",
"      Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. N Engl J Med 1995; 333:229.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2006.375 (World Health Organization, Geneva, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/4\">",
"      Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/5\">",
"      Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009; 150:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/6\">",
"      Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 2007; 13:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/7\">",
"      Kiet VS, Lan NT, An DD, et al. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010; 48:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/8\">",
"      Heysell SK, Houpt ER. The future of molecular diagnostics for drug-resistant tuberculosis. Expert Rev Mol Diagn 2012; 12:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/9\">",
"      Heysell SK, Moll AP, Gandhi NR, et al. Extensively drug-resistant Mycobacterium tuberculosis from aspirates, Rural South Africa. Emerg Infect Dis 2010; 16:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/10\">",
"      Heysell SK, Thomas TA, Gandhi NR, et al. Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study. BMC Infect Dis 2010; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/11\">",
"      Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/12\">",
"      Grandjean L, Moore DA. Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2008; 21:454.",
"     </a>",
"    </li>",
"    <li>",
"     Francis, J. Curry National Tuberculosis Center and California Department of Health. Drug-resistant tuberculosis: a survival guide for clinicians. San Francisco: Francis J. Curry National Tuberculosis Center; 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/14\">",
"      Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/15\">",
"      Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/16\">",
"      Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008; 178:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/17\">",
"      Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/18\">",
"      Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/19\">",
"      Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45:1290.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2006.361. (World Health Organization. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis, 2006). Available at: file://www.who.int/tb/publications/2008/programmatic_guidelines_for_mdrtb/en/ (Accessed on June 03, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/21\">",
"      Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/22\">",
"      Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/23\">",
"      Madariaga MG, Lalloo UG, Swindells S. Extensively drug-resistant tuberculosis. Am J Med 2008; 121:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/24\">",
"      Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/25\">",
"      Hassim S, Shaw PA, Sangweni P, et al. Detection of a substantial rate of multidrug-resistant tuberculosis in an HIV-infected population in South Africa by active monitoring of sputum samples. Clin Infect Dis 2010; 50:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/26\">",
"      Thomas TA, Shenoi SV, Heysell SK, et al. Extensively drug-resistant tuberculosis in children with human immunodeficiency virus in rural South Africa. Int J Tuberc Lung Dis 2010; 14:1244.",
"     </a>",
"    </li>",
"    <li>",
"     Confronting HIV-associated MDR and XDR TB. Symposium convenors: Friedland, G, and Lawn, S. Durban: South African AIDS Conference; 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/28\">",
"      Okwera A, Johnson JL, Vjecha MJ, et al. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults. Int J Tuberc Lung Dis 1997; 1:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/29\">",
"      Dauby N, Muylle I, Mouchet F, et al. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J 2011; 30:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/30\">",
"      Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/31\">",
"      Devasia RA, Blackman A, May C, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63:1173.",
"     </a>",
"    </li>",
"    <li>",
"     The Partners in Health Guide to the Medical Management of Multidrug-Resistant Tuberculosis, Rich ML (Ed), Partners in Health, Boston 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/33\">",
"      Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007; 196 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2006.361. (World Health Organization. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/35\">",
"      O'Donnell MR, Padayatchi N, Master I, et al. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 2009; 13:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/36\">",
"      Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/37\">",
"      Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/38\">",
"      Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/39\">",
"      Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/40\">",
"      Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/41\">",
"      Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/43\">",
"      Wilson D, Hurtado RM, Digumarthy S. Case records of the Massachusetts General Hospital. Case 18-2009. A 24-year-old woman with AIDS and tuberculosis with progressive cough, dyspnea, and wasting. N Engl J Med 2009; 360:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/44\">",
"      Shenoi SV, Brooks RP, Barbour R, et al. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 2012; 7:e31786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/45\">",
"      Mitnick CD, Castro KG, Harrington M, et al. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4:e292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/46\">",
"      McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/47\">",
"      Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 2009; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/48\">",
"      Meintjes G, Rangaka MX, Maartens G, et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/49\">",
"      Friedland G. Tuberculosis immune reconstitution inflammatory syndrome: drug resistance and the critical need for better diagnostics. Clin Infect Dis 2009; 48:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/50\">",
"      Park SK, Kim JH, Kang H, et al. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2009; 13:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/51\">",
"      Lalloo UG, Naidoo R, Ambaram A. Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006; 12:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/52\">",
"      Dravniece G, Cain KP, Holtz TH, et al. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J 2009; 34:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/53\">",
"      van Leuven M, De Groot M, Shean KP, et al. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann Thorac Surg 1997; 63:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/54\">",
"      Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003; 71:7099.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2008.393 (World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing, 2008).",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2006.368. www.stoptb.org. (World Health Organization. The Stop TB Strategy, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/57\">",
"      Shah NS, Pratt R, Armstrong L, et al. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/58\">",
"      Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012; 16:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/53/5978/abstract/59\">",
"      Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375:1798.",
"     </a>",
"    </li>",
"    <li>",
"     Report WHO/HTM/TB/2008.394. (World Health Organization. Antituberculosis drug resistance in the world, Report No.4, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8008 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5978=[""].join("\n");
var outline_f5_53_5978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WHEN TO SUSPECT DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prior to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      During treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AVAILABLE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      First-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Second-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Third-line agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT FOR DOCUMENTED XDR TB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Use of oral first-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use of oral second-line agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Use of third-line agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Sputum cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Drug susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      THERAPEUTIC PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CROSS-RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Injectable agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TREATMENT OF HIV-INFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Initiation of ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Drug interactions and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Immune reconstitution syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      RESECTIVE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      HIV status and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8008|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/8/4224\" title=\"figure 1\">",
"      Clinical characteristics XDR TB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8008|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/51/37680\" title=\"picture 1\">",
"      Sputum Ziehl Neelsen stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8008|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/52/26444\" title=\"table 1\">",
"      Adverse effects - TB and HIV medicines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/44/7886\" title=\"table 2\">",
"      Reports XDR TB rx outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34743?source=related_link\">",
"      Epidemiology of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18375?source=related_link\">",
"      Second-line antituberculous therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_53_5979="Periop factors aggravating OSA";
var content_f5_53_5979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors contributing to acute perioperative aggravation of obstructive sleep apnea (OSA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Depressant influences of anesthetics/sedatives/analgesics on central respiratory drive, upper airway protective reflexes, and arousal responses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intraluminal upper airway narrowing due to post-endotracheal intubation edema, nasal packings, nasal tubes, or hematomas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Forced supine positioning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sleep deprivation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intense rapid eye movement (REM) rebound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Temporary suspension of continuous positive airway pressure (CPAP) therapy due to pain, anxiety, nausea, restlessness, presence of a nasogastric tube, failure to bring the equipment to the hospital, or lack of planning for post-operative application.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5979=[""].join("\n");
var outline_f5_53_5979=null;
var title_f5_53_5980="Clinical features of psychogenic nonepileptic seizures";
var content_f5_53_5980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    More common features distinguishing epileptic seizures and psychogenic nonepileptic seizures*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epileptic",
"       </td>",
"       <td class=\"subtitle1\">",
"        PNES",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration",
"       </td>",
"       <td>",
"        Usually brief, less than 1-2 minutes",
"       </td>",
"       <td>",
"        Usually longer than 2 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes",
"       </td>",
"       <td>",
"        Eyes usually open during event",
"       </td>",
"       <td>",
"        <p>",
"         Eyes often closed",
"        </p>",
"        <p>",
"         Forced eye closure suggests PNES",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motor activity",
"       </td>",
"       <td>",
"        <p>",
"         Stereotyped",
"        </p>",
"        <p>",
"         Synchronized",
"        </p>",
"        <p>",
"         Build, progress",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Variable",
"        </p>",
"        <p>",
"         Forward pelvic thrusting, rolling side to side, opisthotonus",
"        </p>",
"        <p>",
"         Wax and wane",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vocalization",
"       </td>",
"       <td>",
"        Uncommon, especially during convulsion",
"       </td>",
"       <td>",
"        May occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged ictal atonia",
"       </td>",
"       <td>",
"        Very rare",
"       </td>",
"       <td>",
"        May occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incontinence",
"       </td>",
"       <td>",
"        Common in convulsive seizures",
"       </td>",
"       <td>",
"        Less common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autonomic signs",
"       </td>",
"       <td>",
"        Cyanosis, tachycardia common with major convulsion",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postictal symptoms",
"       </td>",
"       <td>",
"        <p>",
"         Usually confused, drowsy",
"        </p>",
"        <p>",
"         Headache common",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         May rapidly awaken and reorient",
"        </p>",
"        <p>",
"         Headache rare",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * No single feature is sensitive or specific for epileptic versus psychogenic nonepileptic seizures.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5980=[""].join("\n");
var outline_f5_53_5980=null;
var title_f5_53_5981="Antineoplastic drugs that act as vesicants or irritants";
var content_f5_53_5981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antineoplastic drugs that act as vesicants or irritants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vesicants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amsacrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bendamustine*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin (concentrations &ge;0.5 mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dactinomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daunorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Docetaxel (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epirubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idarubicin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposomal vincristine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechlorethamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitoxantrone (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxaliplatin (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paclitaxel (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trabectedin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinblastine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vindesine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinorelbine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Irritants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arsenic trioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bortezomib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Busulfan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carboplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cladribine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dacarbazine&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Docetaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluorouracil/floxuridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemcitabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irinotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ixabepilone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposomal daunorubicin&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liposomal doxorubicin&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melphalan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitoxantrone&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxaliplatin&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paclitaxel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptozocin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teniposide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiotepa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topotecan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trastuzumab emtansine&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Although bendamustine is classified as a vesicant, postmarketing reports suggest that extravasation may lead to soft tissue injury.",
"     <br>",
"      &bull;&nbsp;May have vesicant properties, depending on the concentration of volume of drug extravasated. As an example, extravasation of large volume (&gt;20 mL) of concentrated cisplatin (&gt;0.5 mg/mL) may produce tissue necrosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5981=[""].join("\n");
var outline_f5_53_5981=null;
var title_f5_53_5982="Contents: Primary care ENT";
var content_f5_53_5982=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care ENT",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care ENT",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Laryngology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16009\">",
"           Hoarseness in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/10/33960\">",
"           Laryngopharyngeal reflux",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/30999\">",
"           An overview of rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13801\">",
"           Anatomy and etiology of taste and smell disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1690\">",
"           Approach to the adult with epistaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43527\">",
"           Bad breath",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/49/34584\">",
"           Clinical presentation, diagnosis, and treatment of nasal obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11608\">",
"           Differential diagnosis of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/16/8458\">",
"           Eustachian tube dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18455\">",
"           Evaluation and treatment of taste and smell disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7558\">",
"           Evaluation of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18777\">",
"           Gingivitis and periodontitis in adults: Classification and dental treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18824\">",
"           Motion sickness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11431\">",
"           Overview of craniofacial pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22568\">",
"           Salivary gland stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35176\">",
"           Tonsillectomy in adults: Indications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Otology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/33/12823\">",
"           Cerumen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35397\">",
"           Ear barotrauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/6/26727\">",
"           Etiology and diagnosis of tinnitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10490\">",
"           Etiology of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39429\">",
"           Evaluation of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39300\">",
"           Hearing amplification in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/61/32729\">",
"           Meniere disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18082\">",
"           Patient information: Tinnitus (ringing in the ears) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41896\">",
"           Presbycusis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/25/38296\">",
"           Sudden sensorineural hearing loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/57/25495\">",
"           Treatment of tinnitus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-A98729318D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_53_5982=[""].join("\n");
var outline_f5_53_5982=null;
var title_f5_53_5983="Triquetral fracture difficulty";
var content_f5_53_5983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triquetral fracture difficulty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The difficulty of identifying a fracture of the triquetrum using standard anterior-posterior radiographs of the wrist is apparent in this image, in which the superimposed shadow of the pisiform obscures the fracture. Note the small density (arrow) near the ulnar styloid which could represent a fracture fragment or a possible concomitant lunate fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_53_5983=[""].join("\n");
var outline_f5_53_5983=null;
